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Type 2 diabetes mellitus (T2DM) is a global pandemic, with prevalence rapidly rising in South 
Africa. T2DM is characterized by insulin resistance, leading to hyperglycaemia which induces 
oxidative stress (OS) and inflammation with subsequent complications. Betulinic acid (BA), a 
ubiquitous plant triterpenoid, has many proven benefits including antioxidant (AO) properties. 
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor which binds to triterpenes 
and promotes glucose uptake and stimulates cytoprotective and anti-inflammatory effects. This study 
investigated the potential of BA to modulate cytoprotective responses through PPARγ in response to 
hyperglycaemic (HG) induced OS in a human hepatoma (HepG2) liver cell model. HepG2 cells were 
cultured under normoglycaemic (NG) and HG conditions and subsequently treated with 5µM and 
10µM BA. Spectrophotometric [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) and lactate dehydrogenase (LDH) assays] and luminescent (ATP assay) principles were 
employed to assess viability of the chosen BA concentrations. Phosphorylation of the insulin receptor 
β-subunit (IRβ) was assessed via Western blot to confirm BA’s anti-HG effects. Intracellular reactive 
oxygen species (ROS) levels were assessed via fluorescence using the                                            
2′,7′-dichlorodihydrofluorescein-diacetate (H2DCF-DA) assay, and oxidative stress biomarkers were 
quantified spectrophotometrically, via use of the thiobarbituric acid reactive substances (TBARS) 
assay for lipid peroxidation, and protein carbonyl assay (PCA). Intracellular AO potential was 
measured via luminometric quantification of reduced glutathione (GSH). Western blots quantifying 
protein expression of PPARγ, nuclear factor erythroid 2-related factor2 (NRF2), phosphorylated 
NRF2 (pNRF2), sirtuin3 (SIRT3), PPARγ coactivator 1α (PGC1α), superoxide dismutase 2 (SOD2), 
catalase (CAT), uncoupling protein 2 (UCP2), lon protease (LONP1) and nuclear factor κ-B (NFκB) 
as well as quantitative polymerase chain reaction (qPCRs) assessing gene expression of glutathione 
peroxidase (GPx1), NRF2, SIRT3, PGC1α and micro-RNA 124 (miR124) were run to elucidate the 
molecular mechanism behind the cytoprotective response of BA. The MTT, ATP and LDH assays 
confirmed cell viability, lack of toxicity and stable energy output, while TBARS, DCF and PCA 
confirmed a reduction of ROS and its biomarkers. A preliminary Western blot of IRβ confirmed BA’s 
anti-hyperglycaemic actions at a prime concentration of 5µM BA. Further, Western blots also 
confirmed an AO-induced protective mechanism at 5µM BA originating from the PPARγ/NRF2 
positive feedback loop, further involving SIRT3 (p<0.0001), PGC1α (p=0.0025), LONP1 (p<0.0001), 
and AOs:  SOD2 (p<0.0001), CAT (p=0.0003) and UCP2 (p<0.0001). The GSH assay and mRNA 
levels of PGC1α (p<0.0001), NRF2 (p<0.0001), SIRT3 (p<0.0001) and GPx1 (p<0.0001) further 
confirmed the mechanism, while miR124 levels (p=0.0093) hinted at epigenetic regulation between 
the transcription factors.  Additionally, BA was found to downregulate NFκB (p<0.0001) in the HG 
state possibly combatting ROS-induced inflammation. 
xvi 
 
In conclusion, BA illustrated cytoprotective effects on HG induced OS at an optimum concentration 
of 5µM, by upregulating the AO response and reducing ROS. Thus, BA may be considered an 




















CHAPTER 1: INTRODUCTION 
 
Diabetes is a global pandemic, with more than 90% of cases identified as type 2 (Wu et al., 2014). 
Hyperglycaemia due to insulin resistance is a prominent feature of  T2DM, promoting inflammation 
and excessive ROS formation, with consequent diabetic complications (Collins et al., 2018). 
Basal levels of ROS occur under physiological conditions, albeit minimally, as a result of electron 
leakage from various complexes within the electron transport chain (ETC), functioning as signalling 
molecules (Collins et al., 2018). Hyperglycaemic conditions partially inhibit complex 3 of the ETC, 
exacerbating ROS production (Rolo and Palmeira, 2006). An increase in ROS beyond the capacity of 
the AO system, results in a phenomenon known as OS, leading to lipid and protein oxidation, and 
mitochondrial dysfunction (Appari et al., 2018). Excessive and prolonged OS has been one of the 
earliest identified pathological mechanisms implicated in diabetic complications, which include 
vascular disorders, neuropathy, nephropathy and cardiovascular disease amongst others (Appari et al., 
2018). Recent studies suggest that addressing OS is a strategic therapeutic intervention to address 
diabetic complications (Guzik and Cosentino, 2018, Saha and Ghosh, 2012, Li et al., 2014).  
Of particular concern is the aberrant AO system brought about by the diabetic state. Glycation results 
in impaired activity of many AO enzymes including SOD2, GPx1 and CAT (Szaleczky et al., 1999). 
SOD2 enzymatically converts superoxide radicals into the less deleterious hydrogen peroxide. This 
peroxide is further detoxified into unreactive H2O via the action of the predominantly cytosolic 
enzyme CAT, and the predominantly mitochondrial enzyme GPx1, aided by the non-enzymatic 
cofactor, glutathione (Birben et al., 2012). In addition to the impaired AO activity, high levels of both 
intramitochondrial and cytosolic ROS, induced by diabetes, further depletes any remaining AO 
reserves (Phaniendra et al., 2015). 
Uncoupling protein 2, a mitochondrial membrane protein, has a somewhat distinctive modulation of 
both AO response as well as ROS production, making it particularly advantageous in the diabetic 
setting. UCP2 is a protein that uncouples the ETC from oxidative phosphorylation (OXPHOS), 
dissipating the energy potential across the inner mitochondrial membrane, thus mitigating ROS 
production (Pierelli et al., 2017). UCP2 indirectly regulates the AO response by altering the 
NAD+/NADH ratio to promote SIRT3 AO activity (Sosa-Gutiérrez et al., 2018). 
Sirtuin 3 is a NAD-dependant deacetylase, which activates many AO-related proteins, e.g. SOD2 
(Chen et al., 2011). Additionally, SIRT3 activates LONP1, which plays a role in degradation of  
oxidatively damaged proteins, thus preventing further ROS-induced toxicity (Gibellini et al., 2014). 
2 
 
Different theories explore PGC1α’s role in the transcriptional regulation of SIRT3, with one of them 
involving NRF2 as a transcription factor (Song et al., 2017). Earlier literature reports of a positive 
feedback loop existing between SIRT3 and PGC1α, with both potentiating each other, as well as the 
AO profile (Kong et al., 2010). 
Under OS conditions, the cell attempts to modulate the AO response via transcriptional regulation. 
Transcription factor NRF2, along with its positive feedback partner PPARγ, and its co-activator 
PGC1α, transcribe for a plethora of AO proteins including SOD2, GPx1, CAT and UCP2 (Valle et al., 
2005, Lee, 2017). 
The phenomenon of epigenetics has been extensively studied in relation to AO modulation. 
Epigenetics involves the alteration of a gene’s expression without altering the genetic code, and 
includes mechanisms such as methylation, deacetylation and microRNA (miRNA) regulation. 
MiRNAs are a class of small noncoding RNAs that post-transcriptionally regulate gene expression 
(Guzik and Cosentino, 2018). MiR124 is relevant because of its association with PPARγ, NRF2 and 
NFκB. The AO and anti-inflammatory effects of miR124 are due to this association. Thus, miR124 
acts to further potentiate the cytoprotective profile. 
Exogenous compounds may be used to speed up or heighten the AO-response. Certain secondary 
plant metabolites, e.g. triterpenes, display various pharmacological benefits, including AO effects, 
while being devoid of pronounced toxicity (Jäger et al., 2009). Betulinic acid, a ubiquitous, 
pentacyclic triterpene, which has been used commonly in natural healing, exerts its AO response via 
binding to PPARγ (Brusotti et al., 2017). Furthermore, triterpenes are proven to directly 
phosphorylate and activate NRF2 (Loboda et al., 2012). Betulinic acid is found in white birch bark, in 
the easily convertible form of betulin (Yogeeswari and Sriram, 2005). A wide range of research has 
proven numerous pharmacological benefits of BA, including antioxidant, anti-diabetic and anti-
inflammatory effects (Szuster-Ciesielska and Kandefer-Szerszeñ, 2005, Wang et al., 2016, Silva et al., 
2016). 
A deleterious repercussion of OS is the activation of the inflammatory pathway. These phenomena are 
tightly linked via a positive feedback loop, with HG induced ROS being an activation signal for 
inflammation and vice versa (Sharma et al., 2018). Reactive oxygen species also indirectly promote 
inflammation via NFκB activation (Morgan and Liu, 2011). NFκB activation is considered a central 
event early in the pathophysiology of diabetes, and is responsible for the transcription of cytokines, 
chemokines and other pro-inflammatory molecules (Patel and Santani, 2009).  
As an extension of their AO effect, multiple proteins, including NRF2, PPARγ and PGC1α, act to 
inhibit NFκB, thus reducing ROS driven inflammation (Wahli, 2008, Eisele et al., 2015, Guzik and 
Cosentino, 2018). Furthermore, PPARγ modulates miR124 expression to exert its anti-inflammatory 
action via targeting NFκB (Wang et al., 2017).  
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The liver plays a central role in energy homeostasis with regards to regulation of carbohydrate and 
lipid metabolism, derangements of which contribute to the pathophysiology of T2DM. Studies show 
that the HepG2 cell line, despite being a cancer cell-line, closely mimics the in vivo situation with 
regards to glucose metabolism and hence is ideal for generating a HG model (Sefried et al., 2018). 
Given the central role of mitochondrial dysfunction and OS in diabetic pathogenesis, the described 
cytoprotective networks are highly relevant in identifying novel therapies. With multiple lines of 
research revealing BA’s antidiabetic nature, as well as separately proving its AO identity, a 
conjunctive idea was generated, to assess BA’s AO capabilities in the presence of hyperglycaemia. 
Thus, this study’s unique approach to BA combatting OS induced by HG conditions may provide a 
basis for future ubiquitous, natural methods of intervention to limit resultant T2DM complications, 
especially in low and middle-income countries. 
Research Questions 
• Does BA exert cytoprotective properties in HepG2 cells under HG conditions?  
• What is the underlying mechanism of BA-induced cytoprotection in HepG2 cells during HG 
conditions?  
Aim 
To determine the cytoprotective effects of BA on HG-induced OS in HepG2 cells, by assessing 
mitochondrial maintenance, ROS repercussions, and the AO-response. 
Objectives: 
1) To determine an ideal BA concentration in HepG2 cells that does not negatively affect energy 
output, viability or metabolism via: 
• Assessment of cell viability and energy output using the MTT and ATP assays. 
• Assessment of cytotoxicity/necrosis (membrane leakage) via the LDH assay. 
2) To assess BA’s anti-HG effects by determining tyrosine phosphorylation of IR via a PY20 western 
blot. 
3) To determine ROS: 
• Using the H2DCF-DA assay. 
• And its effect on oxidative damage to macromolecules via malondialdehyde (MDA) and 
protein carbonyl quantification. 
• And how it influences protein expression of NFκB p65. 
4) To determine the AO response of BA in a HepG2 model by measuring: 
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• Protein expressions of NRF2, pNRF2, PGC1α, SOD2, Catalase, SIRT3, PPARγ, LONP1, 
UCP2, using western blots. 
• Gene expressions of PGC1α, SIRT3, GPx1, NRF2, using qPCR. 
• Reduced GSH levels via luminometry. 
• Expression of miR124 (involved in epigenetic regulation of AO pathways) using qPCR. 
Hypothesis 
It was hypothesized that BA, via modulation of the PPARγ/NRF2 positive feedback loop, elevated 





















CHAPTER 2: LITERATURE REVIEW 
2.1) Diabetes 
Metabolic diseases are a major cause of morbidity and mortality in both developed and developing 
countries and place an enormous burden on healthcare. Metabolic syndrome (MetS) results from several 
factors that increase an individual’s risk for diabetes and cardiovascular disease (CVD), including 
obesity (visceral), dyslipidaemia, hypertension and elevated fasting glucose (Collins et al., 2018). This 
necessitates efforts towards the development of new and innovative mechanisms to prevent and combat 
this worldwide epidemic, by specifically looking at ubiquitous and renewable sources of intervention. 
Diabetes is a global pandemic, with more than 90% of cases being T2DM (Wu et al., 2014). The 
International Diabetes Federation (IDF) estimated 451 million adult diabetics in 2017,  predicted to 
escalate to 693 million by 2045 (Cho et al., 2018). A similar trend is being observed in South Africa. 
In the year 2000, the prevalence of T2DM in South Africa was 5.5% of the population above 30 years 
of age, rising to 9% in 2009 (Pheiffer et al., 2018). The number of patients has quadrupled in the past 
30 years, and diabetes is recorded by World Health Organisation (WHO) as the seventh leading cause 
of mortality (2018). Globally, 1 in 11 adults has diabetes mellitus, and  almost half of this population is 
undiagnosed (Cho et al., 2018). Furthermore, diabetes mellitus accounts for 12% of global health 
expenditure, creating enormous economic burden (Zhang et al., 2010). 
T2DM is distinguished from type 1 diabetes (an autoimmune disorder characterised by compromised 
pancreatic insulin secretion) in that insulin may still be sufficiently produced; however, the muscle, fat, 
and liver are unable to respond to insulin and hence fail to reduce blood glucose levels. This 
phenomenon is known as insulin resistance and increases circulating glucose levels (hyperglycaemia) 
which contributes to the pathogenesis of T2DM (Aronoff et al., 2004). 
2.2) Glucose uptake and disposal 
Glucose cellular uptake is facilitated by binding of insulin to the insulin receptor. The insulin receptor 
is a transmembrane tyrosine kinase receptor, which after insulin binding, triggers auto-
phosphorylation of the tyrosine residues within the β subunit (Czech, 1985). Phosphorylation 
facilitates the recruitment of adaptor proteins (insulin receptor substrate, protein phosphatases), 
promoting glucose homeostasis (Berg et al., 2002). Autophosphorylation generates an insulin receptor 
substrate 1 (IRS-1) binding site. Phosphorylation of IRS-1 results in a phosphoinositide-3-kinase–
protein kinase B/Akt (P13K/PIP3/PKB) transduction pathway. Protein kinase B  promotes Glucose 
Transporter 4 (GLUT4) glucose uptake and inhibits glycogen synthase kinase, thus promoting 
glycogenesis (Berg et al., 2002). 
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The insulin receptor, in conjunction with other regulatory proteins including PPARγ and PGC1α, are 
implicated in promoting glucose uptake and in some cases disposal (Berg et al., 2002, Wu et al., 2014, 
Bonen et al., 2009). This mechanism of glucose disposal is generally facilitated by insulin and is hence 
impaired in T2DM. Insulin promotes glucose entry into cells via recruitment of glucose transporters, 
and promotes glycogenesis, glycolysis and entry of acetyl coenzyme A (acetyl-CoA) into the 
mitochondria to promote lipogenesis (Aronoff et al., 2004). Prolonged HG conditions, however, have 
the potential to glycate the IR (Rhinesmith et al., 2017). 
2.3) Hyperglycaemia and oxidative stress 
In T2DM, hyperglycaemia can enhance production of free radicals, including ROS. This disruption to 
redox balance contributes to diabetic complications (Nishikawa et al., 2000). Enhanced glycolysis 
results in increased oxidation of glyceraldehyde-3-phosphate to 1,3 diphosphoglycerate, due to 
increased NADH/NAD+ ratio redox imbalance. Enhanced polyol pathway results in an increase in 
fructose and sorbitol, also increasing the NADH/NAD+ ratio (Phaniendra et al., 2015). Furthermore, 
auto-oxidation of glucose generates ketoaldehydes and various ROS (H2O2, OH●, O2●-). To further 
compound the situation, the HG state increases methylglyoxal levels, forming advanced glycation end-
products (AGEs) (Brownlee, 2001, Nishikawa et al., 2000). 
2.3.1) Advanced Glycation End-products 
In T2DM, the excess glucose in circulation covalently binds to cellular macromolecules (proteins, fats, 
DNA, and RNA) leading to AGE formation, which bind to receptors for advanced glycation end 
products (RAGE), promoting ROS formation and diminishing the AO capacity (Collins et al., 2018) 
(Figure 2.1). AGE/RAGE binding impairs muscle healing and contractile function and promotes 
metabolic disturbance, insulin resistance, adipokine expression, fibrosis and collagen cross-linking, all 
contributing to the multitude of complications of T2DM. Furthermore, AGE/RAGEs promote increases 
in inflammation, apoptosis and necrosis via the NFκB/mitogen-activated protein kinase (MAPK) 




Figure 2.1 : Causation and adverse outcome of AGE/RAGE formation and binding (prepared by 
author). 
2.3.2) Mitochondrial-derived reactive oxygen species 
Mitochondria are referred to as metabolic hubs of cells; they harbour the bulk of oxidative and redox 
processes, ensuring an abundant supply of ROS. The ETC is a source of endogenous ROS. Electron 
leakage out of the ETC occurs mainly at complexes I and III resulting in superoxide anion radical 
formation (Andreyev et al., 2005) (Figure 2.4). Hyperglycaemic conditions promote mitochondrial 
dysfunction; the tricarboxylic acid (TCA) cycle produces excess electron transfer donors that enter the 
ETC, resulting in partial inhibition of complex III, amplifying superoxide radical levels (Rolo and 
Palmeira, 2006). Other components within the organelle also contribute to ROS production e.g. 
monoamine oxidase and α-ketoglutarate dehydrogenase (Phaniendra et al., 2015). 
2.4) Reactive oxygen species and Oxidative stress 
Oxygen in molecular form is more susceptible to e- transfer, due to the presence of two unpaired 
electrons. O2 forms a reactive anion, known as superoxide, when it accepts an electron, which can form 
hydroxyl radicals and H2O2 via sequential reduction (Apel and Hirt, 2004). ROS can thus be defined as 
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unstable, O2-derived molecules (Gorrini et al., 2013). Table 2.1 lists the most physiologically abundant 
ROS, as well as classifies their radical status. 
Despite its pathological associations, basal levels of ROS are essential for cell maintenance. ROS are 
signalling molecules involved in gene transcription, protein synthesis, post-translational modifications, 
cellular differentiation, apoptosis and defence. A fine balance exists between pro-oxidants and 
antioxidants in every cell. However, due to either diminished AO capacity or an increase in ROS, the 
balance can be disrupted, favouring pro-oxidants. This is known as oxidative stress (Appari et al., 2018). 
2.5) Effects of reactive oxygen species 
Recent research has identified ROS as playing a pivotal role in various physiological processes, and has 
linked excess ROS to a diverse group of pathological manifestations, including liver damage, asthma, 
neurodegenerative diseases, cancer and aging (Phaniendra et al., 2015). High ROS levels initiate 
inflammation via NFκB. Increased ROS and concomitant inflammation are proven to stimulate MetS, 
with concomitant diabetes and cardiovascular disease (Collins et al., 2018). 
ROS accumulation can result in endoplasmic reticulum (ER) stress. ER stress results in protein 
misfolding/unfolding, interfering with protein synthesis and calcium homeostasis, and prevents removal 
of irregular proteins, thus initiating necrosis/apoptosis (Collins et al., 2018). ROS accumulation is also 
associated with lipid peroxidation and resultant protein carbonylation.  
 
Table 2.1: Most physiologically abundant ROS classified according to radical status (prepared by 
author). 
 
2.5.1) Lipid peroxidation and protein carbonylation 
An important mechanism to consider in free radical mediated cell injury is lipid peroxidation and 
concomitant protein carbonylation. The autocatalytic uncontrolled process of lipid peroxidation’s 
consequences are 2-fold: this involves the direct attack of cell membrane structures, and indirect 
mechanisms of release of reactive products (Hauck and Bernlohr, 2016).  
Non-radicals Radicals 
Hydrogen Peroxide: H2O2 Superoxide: O2
●- 
Ozone : O3 Hydroxyl: OH● 
Hypochlorous acid: HOCl Hydroperoxyl: HO2● 
Singlet Oxygen: O2 Alkoxyl: RO
● 
Alkyl hydroperoxide: ROOH Alkperoxyl: RO2● 
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Peroxidation alters the biophysical properties of membranes by attacking polyunsaturated fatty acids 
(PUFAs), and is associated with aging and metabolic diseases. Peroxidative PUFA attack 
compromises the membranes ability to act as both a simple and selective barrier (Cheeseman, 1993). 
Proteins involved in active transport are affected; loss of calcium pump activity and hence calcium 
homeostasis was observed in a hepatocyte model due to lipid peroxidation (Albano et al., 1991, 
Cheeseman, 1993). Furthermore, the inner mitochondrial membrane is particularly susceptible to lipid 
peroxidation. Here, cardiolipin maintains cristae structure and stabilizes the ETC and, understandably, 
oxidation of this lipid is associated with impaired respiration and mitochondrial dysfunction, linked to 
atherosclerosis and obesity (Hauck and Bernlohr, 2016, Zhong et al., 2014). 
The indirect effects of lipid peroxidation stem from the reactive nature of the products and/or 
intermediates of peroxidation. Amongst oxidative species, lipids, due to high stability and 
diffusibility, have a large functional boundary, with some lipid aldehydes even diffusing extra-
cellularly. These reactive lipid aldehydes post translationally modify cysteine , histidine and lysine 
residues, resulting in protein carbonylation (Hauck and Bernlohr, 2016). Frohnert and Bernlohr (2013) 
labelled this lipid peroxidation-induced protein carbonylation as being the determining factor in 
mitochondrial dysfunction (Frohnert and Bernlohr, 2013). 
Mitochondria are particularly vulnerable to carbonylation. Substantial carbonylation of ETC 
complexes as well as ATP synthetases has been observed in various models resulting in reduced ATP 
generation capacity (Wen and Garg, 2004). Furthermore, protein carbonylation of mitochondrial α-
ketoglutarate dehydrogenase and aconitase are implicated in TCA cycle disruption (Yarian et al., 
2005). 
Carbonylation results in protein misfolding due to its effects on chaperones and machinery regulating 
polypeptide conformations. Alterations in protein folding may prevent proper cellular localization as 
well as the function of interacting partners. These proteins form toxic aggregates, (Dalle‐Donne et al., 
2006). Tissue deposition of protein aggregates are being increasingly associated with metabolic 
disorders, with Mukherjee et al. (2015) describing T2DM as a ‘protein misfolding disease’ 
(Mukherjee et al., 2015). 
Generally, moderately carbonylated proteins are proteasomally degraded, whereas, proteins that are 
heavily carbonylated, form high molecular weight aggregates, thus resisting degradation and hence 
accumulate. Excess oxidation potentiates cross linking, providing a structural constraint preventing 
entry into the catalytic sites of the proteasomal enzymes (Dalle‐Donne et al., 2006). Aggregation and 
inhibition of degradation may result in apoptosis (Powell et al., 2005). Under high stress conditions, 
however, the mitochondria use a specific proteolytic digester of oxidized proteins known as LONP1 
(Ngo et al., 2013). 
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2.6) Lon Protease  
Lon protease is a nuclear-encoded, mitochondrial, ATP dependant, serine peptidase that indirectly 
complements the AO response by degrading oxidized proteins (Bota and Davies, 2016).   
Pinti et al (2016) described LONP1 as a “master-regulator of mitochondrial functions”. 
Mitochondrial DNA replication and mitogenesis as well as chaperone systems have been implicated in 
LONP1 function (Bota and Davies, 2016). Furthermore, a decrease in LONP1 activity affects the levels 
of proteins involved in the stress response, ATP production and ribosomal assembly (Pinti et al., 2016). 
Cells with decreased/deficient LONP1 activity experience a decrease in the level of ETC complexes I, 
III and IV which leads to defects in cellular respiration (Key et al., 2019).  
In OS conditions, nuclear transcription of LONP1 occurs, followed by translation into a precursor 
polypeptide. This polypeptide contains a mitochondrial target sequence, allowing it through the 
mitochondrial membranes into the matrix. The target sequence is then cleaved off, producing a newly 
processed protein (Venkatesh et al., 2012). Gibellini et al., (2014) stated that changes in LONP1 mRNA 
levels, protein activity, and gene expression are not always correlated, implying high levels of post-
translational modification (Gibellini et al., 2014). During oxidative stress,  SIRT3 deacetylates LONP1, 
post-translationally activating it, which in turn eliminates damaged proteins due to oxidative stress via 
proteolysis (Gibellini et al., 2014). If these proteins are not removed they may cross link and lead to 
toxicity (Gounden and Chuturgoon, 2017).  
2.7) Inflammation and reactive oxygen species 
Metabolic changes observed in diabetes involving hyperglycaemia, hyperlipidaemia and insulin 
resistance with an associated increase in OS and inflammation, drive diabetic complications such as 
nephropathy , atherosclerosis, cardiomyopathy, neuropathy and retinopathy (Sharma et al., 2018). 
A cyclical process exists between inflammation and oxidative stress. Increased pro-inflammatory 
cytokine expression stimulates ROS levels. Reciprocally, high ROS levels result in increased pro-
inflammatory cytokine expression (Figure 2.1) (Sharma et al., 2018). This positive feedback loop drives 
a highly pro-inflammatory and pro-oxidant state, proven deleterious to T2DM, exacerbating 
complications. Integral to this positive feedback loop, is the role of NFκB (Morgan and Liu, 2011).  
2.7.1) Nuclear factor κ B 
In T2DM, HG-induced ROS is an important inflammasome activating signal. This direct role is well 
researched, however another role also exists, in which ROS, via its actions on NFκB, indirectly 




In its inactive state, NFκB is sequestered within the cytoplasm by its inhibitor, IκB. When this inhibitor 
undergoes phosphorylation and resultant degradation, NFκB (p65 subunit) is activated and translocates 
into the nucleus (Nishikori, 2005). Previously, it was concluded that high levels of hydrogen peroxide 
activate NFκB, however more recently, Kim et al. (2008) demonstrated that ROS indirectly activates 
NFκB via activation of AKT. AKT activation, and subsequent IKK phosphorylation, results in oxidation 
and dissociation of IκBα inhibitory proteins, thus allowing phosphorylation of ser-276 and hence NFκB 
translocation (Kim et al., 2008, Schreck et al., 1991). 
NF-κB is a rapidly inducible transcription factor that affects a wide range of cellular responses via gene 
induction. It is considered integral in inflammation as it is involved in transcriptional activation of 
cytokines, chemokines, and various inflammasome components (Sharma et al., 2018). However, NFκB 
plays a dual role. Besides being activated by ROS, for inflammatory purposes, NFκB also further 
enhances ROS production by inducing expression of various proteins. NFκB directly upregulates 
NADPH oxidase 2 (NOX2), a devoted ROS producer, and cyclo-oxygenase 2 (COX2), an enzyme 
producing superoxide by-products, thus promoting OS (Figure 2.2) (Morgan and Liu, 2011). 
NFκB’s pivotal role in both ROS and inflammation warrants its need to be regulated by various 
antioxidant transcription factors and co-factors. Collino et al. (2005) demonstrated that agonist binding 
to PPARγ successfully controlled oxidative stress and inflammation via direct suppression of NFκB 
and its downstream ROS generators (Collino et al., 2005). Furthermore, PPARγ’s co-activator, PGC1α, 
has been implicated in promoting an anti-inflammatory environment in skeletal muscle cells via 
reduction of NFκB activity (Figure 2.9) (Eisele et al., 2015). Interestingly, Wardyn et al. (2015) reported 
a form of molecular crosstalk existing between NFκB and the well-known AO-regulator NRF2. He 
noted that absence of NRF2 is linked to an upsurge in oxidative stress, exacerbating NFκB-induced 
cytokine production (Figure 2.2) (Wardyn et al., 2015). NFκB’s direct link to ROS and involvement in 
many proteins within the cytoprotective network emphasises the need to further study this transcription 




Figure 2.2: Relationship between NFκB, ROS and inflammation and its regulation by antioxidant-
related proteins (prepared by author). 
2.8) Intramitochondrial Antioxidant defence systems 
Due to their high susceptibility to redox damage, mitochondria possess an innate antioxidant system. 
Antioxidants are phenol containing compounds, which inhibit substrate oxidation, thus neutralizing the 
harmful effects of ROS (Noori, 2012). Antioxidants prevent free radical producing oxidation reactions 
by being oxidized themselves, thus removing other radical intermediates and are thus known as 
reducing agents (Lü et al., 2010). These free radical scavengers may be enzymatic (SOD, GPx1) or non-
enzymatic (GSH) (Noori, 2012). 
2.9) Reactive oxygen species detoxification 
Detoxification of ROS occurs both intra- and extra-mitochondrially. SOD2, located in the mitochondrial 
matrix, is the first line of defence that plays a crucial role in detoxifying free superoxide radicals (O2●-) 
(Figure 2.3). It is an AO metalloenzyme with a manganese centre which catalyses portioning of the 
superoxide radical. SOD2 thus, transforms the superoxide radical into either H2O2 or diatomic oxygen, 
ensuring that basal ROS levels are maintained (Ighodaro and Akinloye, 2018). SOD2 has been proven 
vital for mitochondrial function in oxidative tissue, however, superoxide detoxification does occur in 
the absence of SOD2, albeit at a lower rate (Ighodaro and Akinloye, 2018).  
Due to its important role, SOD2 is well regulated. Both NRF2 and PPARγ transcribe for SOD2 and, 
SIRT3 deacetylates the protein, in response to hyperglycaemia, thus enhancing its AO-activity (Lee, 
2017, Gounden et al., 2015). Additionally, PGC1α associates with the SOD2 promoter, thus inducing 
its expression (Figure 2.3 and Figure 2.7)(Valle et al., 2005).  
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Hydrogen peroxide is not as toxic as O2●-, however, it can oxidize iron-sulphur centres and thiol groups, 
as well as be converted to mutagenic OH● (Sharma et al., 2012). Thus, the mildly reactive H2O2 is 
further detoxified by either CAT or GPx1 into water (Figure 2.3). Catalase is an AO protein, found most 
abundantly in peroxisomes and cytosol, which has the capability to detoxify millions of hydrogen 
peroxide molecules. It structurally contains 4 long polypeptide chains and 4 porphyrin haem rings, 
which detoxify the H2O2 (Kabel, 2014). According to Kabel (2014), CAT detoxifies H2O2 in a basic 
catalytic manner and a peroxidatic manner (Kabel, 2014). The catalytic reaction generates H2O and O2 
while peroxidatic detoxification uses the O2 from H2O2 to oxidize H-donors and also produces H2O 
(Kabel, 2014). Transcription factors PPARγ, NRF2, and PGC1α (Figure 2.9) are implicated in the 
transcriptional activation of CAT (Lee, 2017, Valle et al., 2005). 
2.9.1) Glutathione peroxidase 1/glutathione (reduced) antioxidant mechanism 
Yet another enzyme implicated in H2O2 detoxification, is GPx1. GPx1 can be located within the 
cytoplasm, mitochondria, and the nucleus. Both NRF2 and PGC1α are implicated in its transcriptional 
upregulation (Lee, 2017, Valle et al., 2005). A unique amino acid by the name of selenocysteine, located 
on GPx active sites, utilises low molecular weight thiols to detoxify lipid peroxides and H2O2. GSH is 
one of the most common thiols utilised when metabolizing H2O2 to water (Birben et al., 2012). 
GSH is a nonenzymatic AO located both in the mitochondrial matrix and the cytoplasm (Lushchak, 
2012). This free radical scavenger exists in reduced and oxidised forms and is a substrate for GPx1 
activity (Lushchak, 2012). Reduction of H2O2 results in oxidation of GSH to GSSG by GPx1. GSSG is 
reduced back to 2GSH molecules via the action of glutathione reductase (GR) and the cofactor, NADPH 
(Figure 2.3) (Lushchak, 2012). Research has shown that T2DM patients display lower levels of GSH 
synthesis (Sekhar et al., 2011). 
 




2.10) Diabetes and its antioxidant implications 
Of equal importance in the pathological setting, to enhanced ROS, is that of diminished AO capacity. 
In the diabetic case, this extends beyond the concept of excess ROS levels merely depleting the AO 
supplies, leaning toward a more direct effect on antioxidants.  
Numerous studies confirmed the diabetic state as a causal agent in lowering AO levels of CAT, SOD 
and GPx (Loven et al., 1986, Wohaieb and Godin, 1987, Sukalski et al., 1993). Research into this avenue 
provided us with two theoretically firm explanations to the adverse effects of diabetes on AO 
mechanisms.  
The first theory revolves around glycation, the non-enzymatic binding of glucose to proteins bringing 
about functional and structural changes. Szaleczky et al. (1999) speculated that the HG state could result 
in a reduction of AO enzyme capability via enhanced glycation (Szaleczky et al., 1999). 
The second theory involves diabetic-induced modulation of the micronutrient environment. Antioxidant 
enzymes require certain cofactors and micronutrients to express their functionality; CAT requires haem, 
GPx requires selenium and superoxide dismutase utilises copper, zinc or manganese. It was suggested  
that in the diabetic state, alterations of the micronutrient environment affected cofactor/enzyme ratio, 
thus influencing activation statuses of AO enzymes (Szaleczky et al., 1999). Thus, an aberrant AO 
profile and high ROS levels are induced by diabetes. In a possible attempt to offset both these 
aberrations, UCP2 expression is found to be upregulated in the HG state (Sosa-Gutiérrez et al., 2018). 
2.11) Uncoupling Protein 2  
The uncoupling proteins are a family of 5 carriers unique to mammals (Pierelli et al., 2017). They 
consist of 3 U-shaped membrane units of 100 amino acids each, and exist in the mitochondrial inner 
membrane (Su et al., 2017). UCP2 is distributed widely in various tissues, including kidney, spleen, 
pancreas, and is responsible for regulating redox status (Liu et al., 2013). The UCP2 promoter region 
bears  putative response elements for the AO-transcriptional protein, PPARγ (Pierelli et al., 2017) and 
also senses energy levels and aids in mitochondrial maintenance (Su et al., 2017). 
UCP2 aids in rectifying the spatiotemporal imbalance between ROS and AO, most uniquely, by both 
lowering ROS levels and enhancing AO machinery. Although unconventional in its methods, 
uncoupling is considered an AO mechanism (Sosa-Gutiérrez et al., 2018). 
Attenuation of ROS production 
ATP and the ETC are coupled processes. Reducing donors such as NADH and FADH2 provide the ETC 
with substrates. Electron flow is conveyed along the chain, generating energy, forcing H+ ions out of 
the membrane. High levels outside the inner mitochondrial membrane promote re-entry via ATP 
synthase, thus stimulating OXPHOS. The ETC, however, generates small amounts of ROS via 
interactions between electrons and free O2 (Figure 2.4). In HG conditions, tight mitochondrial coupling 
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results in high proton motive force, leading to excess reduction of ETC subunits, and hence increased 
ROS (Souza et al., 2011). 
Uncoupling protein 2 functions as a transmembrane proton channel, thus enabling H+ ions to flow back 
through the membrane instead of through ATP synthase. This proton leakage dissipates the 
electrochemical proton gradient across the inner membrane, uncoupling the ETC from OXPHOS 
(Figure 2.4) (Pierelli et al., 2017). Uncoupling substrate oxidation from ATP production prevents 
defects of one of the processes from affecting the other. This mild uncoupling prevents further 
superoxide production as well as decreases oxidative damage (Pierelli et al., 2017). 
Enhancing antioxidant activity: 
UCP2 indirectly regulates SIRT3 activity. The uncoupling ability of UCP2 allows it to modulate the 
NADH/NAD+ ratio, due to its effects on the ETC. This innate ability is of relevance in HG conditions, 
favoring NADH. The intrinsic ability of NAD+-dependent SIRT3 to sense the ratio then results in an 
increase of SIRT3 activity, which then promotes AO-protein activity to combat ROS (Sosa-Gutiérrez 
et al., 2018).  
 
Figure 2.4: The electron transport chain; endogenous ROS generation; uncoupling of OXPHOS from 







2.12) Sirtuin 3  
Sirtuin 3 is a member of the sirtuin family of deacetylases. It is a soluble protein which is located in the 
matrix of the mitochondria and plays a vital role in many body processes. Hence it is found in abundance 
in many active organs, such as the liver (Hirschey et al., 2011a).    
Initially, SIRT3 is produced enzymatically inactive within the cytosol, and is only activated when 
translocated into the mitochondrial matrix by mitochondrial peptidase. Upon translocation into the 
mitochondrion, SIRT3 undergoes proteolytic cleavage, becoming an active 28kda protein. SIRT3 
functions as a deacetylase, removing the acetyl groups of acetyl-lysine residues on amino acids. This 
reaction requires NAD+ as a cofactor (Hirschey et al., 2011a).  
Transcriptional activation 
A positive feedback loop exists between SIRT3 and PGC1α  (Flick and Lüscher, 2012). PGC-1α induces 
SIRT3 expression (Figure 2.5) by allowing transcription factor estrogen-related receptor α (ERRα) to 
bind to the promoter region of SIRT3. Reciprocally, SIRT3 activates cAMP response element-binding 
protein (CREB) which in turn stimulates PGC1α activation. Interestingly, Song et al. (2017), proposed 
another mechanism of activation in which NRF2 transcribes for SIRT3 with the aid of PGC1α to 
enhance the cellular AO status (Song et al., 2017). 
Oxidative stress 
Sirtuin 3 plays a major role in oxidative stress by increasing AO capacity as well as promoting 
proteolytic digestion of oxidized proteins. 
Sirtuin 3 is regulated in accordance with the oxidative status of the cell; high oxidative stress increases 
SIRT3 expression whereas decreased ROS decreases SIRT3 expression  (Chen et al., 2014). During 
OS, SIRT3 directly targets AOs: SOD2 and isocitrate dehydrogenase (IDH2), activating them by 
deacetylation (Chen et al., 2011, Yu et al., 2012). SIRT3 also indirectly affects AOs: GPx1, SOD2, 
CAT and UCP2 via PGC1α (Fig. 2.3; Fig. 2.5) (Gounden et al., 2015). Furthermore, Someya et al. 
(2010) concluded that SIRT3 reduces oxidative DNA damage via upregulation of the GSH AO 
mechanism (Someya et al., 2010). 
SIRT3 also deacetylates and hence modulates LONP1, which aids in the breakdown of proteins that are 
oxidatively damaged within the mitochondrial matrix (Chen et al., 2014). 
Mitochondrial Metabolism 
Sirtuin 3, considered a metabolic sensor, plays a beneficial role in the regulation and procession of 
mitochondrial metabolism, via direct interaction with many of its aspects e.g. TCA, OXPHOS, ETC. 
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Within the ETC, SIRT3 deacetylates complexes I and II, resulting in precession of the ETC (Liu et al., 
2002). SIRT3 regulates OXPHOS by activating acetyl-CoA synthetase 2 and glutamate dehydrogenase 
(Ahn et al., 2008). 
In the TCA cycle, SIRT3 deacetylates the enzyme aconitase (allowing conversion of citrate to 
isocitrate), succinate dehydrogenase (allowing conversion of succinate to fumarate and allowing 
electrons to transfer to FAD converting it to FADH2), isocitrate dehydrogenase (allowing oxidative 
decarboxylation of isocitrate), as well as GDH and acetyl-CoA synthetase 2 (Fernandes et al., 2015, 
Finley et al., 2011, Yu et al., 2012, Ansari et al., 2017). 
Diabetes and Sirtuin 3 
With regards to the HG state, Gounden et al. (2015) concluded that hyperglycaemia resulted in  
increased expression of SIRT3 to combat the higher levels of ROS associated with this state (Gounden 
et al., 2015). Additionally, SIRT3 also plays an integral role in directly combatting the hyperglycaemia 
by increasing insulin sensitivity and glucose entry into the cell (Hirschey et al., 2011a). Furthermore, a 
series of metabolic abnormalities extrapolated to mimic MetS were observed in mice, following SIRT3 
disruption (Hirschey et al., 2011b). 
 
 
Figure 2.5: SIRT3/PGC1α positive feedback loop in potentiation of the antioxidant profile (prepared 
by author). 
2.13) Epigenetics 
Epigenetics involves the study of post-translational or post-transcriptional modification of gene 
expression as an alternative to alteration of the true genetic code. This concept of chromatin remodelling 
has proven to be an important gene modulator without affecting the DNA sequence, thus resulting in 
heritable changes in cellular phenotype (Guzik and Cosentino, 2018). The epigenetic concept is 
particularly relevant in this case due to its regulation of proteins involved in the AO response. 
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The major mechanisms of epigenetics involve DNA methylation, post-translational histone 
modifications (acetylation/deacetylation) and RNA regulating molecules such as miRNAs (Guzik and 
Cosentino, 2018). 
2.13.1) MicroRNA-124 
MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. They alter 
mRNA stability and inhibit translation via complementary binding to the 3’-UTR of mRNA (Guzik and 
Cosentino, 2018). Alterations of miRNA expression have been noted in diabetes and some miRNAs 
have even been identified as biomarkers for several human diseases. Recent studies highlight a link 
between several miRNA and diabetic-induced OS in the potentiation of T2DM complications (Yu et 
al., 2015, Yildirim et al., 2013). Furthermore, many anti-inflammatory miRNAs have been 
downregulated in T2DM, thus promoting a pro-inflammatory  phenotype (Guzik and Cosentino, 2018). 
MiR124 is involved in many processes including AO, immunity, apoptosis, inflammation, cell 
differentiation, survival, apoptosis, and OS (Yao et al., 2018, Mokabber et al., 2019). Wang et al. (2017) 
revealed that PPAR-γ binds directly to the PPRE on the miRNA124 promoter region, inducing its 
expression. Furthermore, Wang et al. (2017) states that PPARγ activation can inhibit production of pro-
inflammatory cytokines via upregulation of miR124 (Wang et al., 2017). MiR124 exerts its anti-
inflammatory actions by inhibiting translation of the inflammatory signaller, NFκB (Qiu et al., 2015). 
Shu and Zhang (2019) suggests that miR124 stimulates the p13K/AKT/NRF2 pathway, resulting in 
NRF2 transcribing for AO-proteins that combat oxidative stress. However, its regulatory mechanism is 
not fully elucidated (Shu and Zhang, 2019). 
 
Figure 2.6: Relation of miRNA124 to transcription factors and involvement in reducing ROS-induced 




2.14) Nuclear factor erythroid 2-related factor 2  
Nuclear factor erythroid 2-related factor 2 is a transcription factor, regarded as a pivotal modulator of 
the AO response. NRF2 is normally bound to Kelch-like-ECH-associated protein 1 (KEAP1) in the 
cytoplasm and is targeted for ubiquitination and degradation, thus supressing its antioxidant capabilities. 
In the presence of ROS, cysteine residues of KEAP1 conjugate to ROS inducing agents inhibiting 
ubiquitination. This results in nuclear translocation of NRF2 (Figure 2.5) (Lee, 2017). In the nucleus, 
NRF2 interacts with small maf proteins and other coactivators and binds to the antioxidant response 
element (ARE), transcriptionally activating a plethora of AO-related genes including PPARγ, SIRT3, 
retinoid X receptor (RXR), CAT, GPx1, SOD2 (Cho et al., 2010, Chorley et al., 2012, Jeong et al., 
2016, Jin et al., 2016, Cho et al., 2005, Song et al., 2017). 
More recent research, however, explores alternate regulatory mechanisms of NRF2, including 
phosphorylation. Protein kinase C phosphorylates NRF2 in the Neh2 domain at ser-40, thus disrupting 
the NRF2-KEAP1 association promoting translocation and AO-related activity (Bryan et al., 2013).  
The role of the NRF2 pathway in the prevention, delay, and/or reversal of diabetic complications has 
been elucidated. Murine models of NRF2 overexpression indicate that NRF2 activation improves 
insulin sensitivity and can ameliorate diabetes and obesity (David et al., 2017). Furthermore, NRF2 has 
been shown to have an anti-inflammatory role by reducing ROS-dependent inflammation; and a recent 
study by Liu et al. (2017) indicated that an NRF2 activator reduced ROS levels, subsequently reducing 
inflammasome activation, cleavage of caspase 1 and production of interleukin 1β (IL1β) (Liu et al., 
2016).  
2.15 Peroxisome proliferator-activated receptor gamma 
PPARs are a group of nuclear receptors that regulate metabolic pathways including those involving the 
pathophysiology of diabetes and obesity (Brusotti et al., 2017). Steroid/thyroid hormone ligands, eg. 
cortisol, bind to nuclear receptors, functioning in conjunction with proteins to regulate gene expression. 
This binding causes a conformational change that results in either an up-or-downregulation of gene 
expression (Sever and Glass, 2013).  
PPARγ is a nuclear receptor that, once ligand bound, enters the nucleus, heterodimerizes with RXR and 
binds to PPAR response elements (PPREs) on the promoter region of genes (Figure 2.7). PGC1α is one 
of the co-activators required to elicit its action (Figure 2.9). This action recruits a large array of protein 
coactivators, initiating diverse physiological outcomes, including AO response via NRF2, UCP2, SOD, 
CAT, GPx (Kvandova et al., 2016, Pierelli et al., 2017, Polvani et al., 2012, Girnun et al., 2002) 
In addition to its AO capabilities, PPARγ also modulates certain aspects of carbohydrate and lipid 
metabolism. PPARγ-regulated gene expression is involved in fatty acid storage via lipid uptake and 
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adipogenesis as well as improving basal glucose uptake via GLUT4 recruitment (Carvalho, 2017, Rosen 
and Spiegelman, 2001).  
PPARγ also directly influences inflammation. Multiple studies have identified this transcription factor 
as a negative regulator of OS-induced inflammation. In-depth mechanistic research uncovered that 
PPARγ suppresses inflammation via transcriptional repression of several pro-inflammatory 
transcription factors and proteins such as COX2 and NFκB (Wahli, 2008, Polvani et al., 2012, Reddy 
and Standiford, 2010). 
2.16) Crosstalk between PPARγ and NRF2 
Various studies investigated links between PPARγ and NRF2, with some studies hinting at a 
reciprocal regulation between the 2 transcription factors (Reddy and Standiford, 2010, Huang 
et al., 2010a, Polvani et al., 2012). Lee (2017) further investigated this crosstalk, hypothesizing 
a positive feedback loop between these 2 factors (Lee, 2017).  Lee (2017) based his hypothesis on 
various findings including: (i) NRF2 binding to the ARE on PPARγ; (ii) PPRE presence on NRF2; (iii) 
NRF2 inducing RXR upregulation; and (iv) both PPARγ and NRF2   inducing the same AO genes 
(Figure 2.7)(Lee, 2017, Cho et al., 2010, Kvandova et al., 2016, Chorley et al., 2012). Thus, both 
transcription factors upregulate each other and have a collaborative action on AO genes, potentiating 
the AO response to OS.  
Figure 2.7: Collaborative action of NRF2 and PPARγ [Adapted by author from Lee, (2017)]. 
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2.17) Betulinic Acid 
Betulinic acid, a secondary plant metabolite, is ubiquitous in nature, having been identified in many 
fruit, vegetables and the bark of trees (Brusotti et al., 2017). It has been used therapeutically for centuries 
across the globe. In the African continent, BA is an important constituent in a traditional medicinal 
plant, Peltophorum africanum  (Theo et al., 2009). Native Americans used bark containing BA to treat 
diarrhoea and dysentery whereas Russians have reportedly used BA therapeutically since 1834 
(Yogeeswari and Sriram, 2005). 
Betulinic acid is found abundantly in the barks of some trees like the white birch, Betula alba, in the 
form of betulin, which can be easily converted to BA (Yogeeswari and Sriram, 2005). Currently, BA 
can be prepared via various means such as  using the yeast Saccharomyces cerevisiae (baker’s yeast), 
and by recombinant plant and microbial cultures (Zhang et al., 2016). Sousa et al. (2019) explored 
simple transformations to BA, including amination, esterification, sulfonation and alkylation to 
medicinally functionalize BA (Sousa et al., 2019). 
Betulinic acid ((3β)-3-Hydroxy-lup-20(29)-en-28-oic acid)(Fig. 2.8) is a naturally occurring penta-
cyclic triterpenoid with a lupane skeleton containing two functional groups: 3OH and 17COOH 
(Yogeeswari and Sriram, 2005, Sousa et al., 2019). Pentacyclic compounds have 5 rings of atoms in 
their structure (Yogeeswari and Sriram, 2005). A triterpene is a hydrocarbon with no heteroatoms. 
Pentacyclic triterpenes, particularly lupane-type, display various pharmacological effects, while being 
devoid of prominent toxicity (Jäger et al., 2009). Betulinic acid, being a triterpenoid acid,  has a structure 
similar to that of cholesterol, and can thus bind to receptors, e.g. PPARγ, that normally bind to 
endogenous steroid hormones (Heiss et al., 2014). 
 






2.17.1) Betulinic Acid and Peroxisome Proliferator-Activated Receptor Gamma 
Betulinic acid is a PPARγ antagonist. An agonist response typically involves ligand binding 
stimulating gene expression. An antagonist usually competitively binds at the same active site, thus 
preventing agonist binding (Brusotti et al., 2017). PPARγ agonists can exert insulin sensitizing actions 
in T2DM. Thiazolidinediones are agonists currently in use for diabetes, with serious side effects of 
weight gain and cardiac failure (Bermudez et al., 2010). New synthetic agonistic ligands were identified, 
but were later withdrawn due to toxicity, with new antagonistic ligands developed to fill this gap. 
Furthermore, studies show that use of PPARγ antagonists with agonists ameliorate agonist side effects, 
thus providing a niche for BA (Leyvraz et al., 2010). Betulinic acid is the first PPARγ antagonist with 
a solved crystal structure. The crystal structures of the BA/PPARγ complex suggest that another 
molecule can be modelled at a second alternative site. (Brusotti et al., 2017). 
Betulinic acid antagonistically binds with high affinity to its receptor, PPARγ, requiring no 
transactivation. Therefore, it is utilised for its insulin sensitizing and antidiabetic properties (Brusotti et 
al., 2017). Betulinic acid increased basal glucose uptake in adipocytes insulin-independently by up to 
50% (Brusotti et al., 2017). 
2.17.2) Pharmacological benefits  
Betulinic acid has many biological and pharmacological benefits (Zhang et al., 2016). It has been proven 
to possess antimalarial, antiretroviral, immunomodulatory, antiangiogenic, antifibrotic, antioxidant, 
hepatoprotective and anti-inflammatory effects (Zhang et al., 2016). 
Betulinic acid’s thoroughly researched anti-diabetic properties stem from its phosphorylation of IR. 
Castellano et al. (2013) demonstrated that oleanolic acid and triterpenoid analogues synergistically 
enhance IR phosphorylation in Chinese hamster ovary (CHO-IR) cells and that, in the absence of 
insulin, at high concentrations, they can duplicate auto-phosphorylated receptors, concluding that 
triterpenes bind not to the insulin site but onto the β subunits (Castellano et al., 2013). Insulin receptor 
signalling may result in GLUT4 membrane localization. A separate study by  Castro et al. (2014) 
demonstrated BA’s effect on GLUT4 membrane localization for resultant glucose uptake (Castro et al., 
2014). Many of the anti-diabetic effects of the triterpenes involve the  repression of  the polyol pathway, 
AGEs production and are related to activation of NRF2 (Castellano et al., 2013). 
Betulinic acid and other triterpenes act as anti-diabetic agents via alternate pathways including through 
decreased gastro-intestinal glucose absorption, decreased endogenous glucose production and through 
increased insulin biosynthesis, secretion and sensitivity. Triterpenes further improve lipid homeostasis. 
Experimental studies have revealed that these positive effects on glucose and lipid metabolism occur at 
a dose that is not hepatotoxic as evidenced by normal levels of liver enzymes (Silva et al., 2016). Most 
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recently, Kim et al (2019) uncovered BA’s amelioration of hyperglycaemia in a HFD mice model via 
decreased plasma glucose and increased insulin secretion (Kim et al., 2019).  
Wang et al. (2016) proved BA’s anti-inflammatory effect to diabetic-induced renal inflammation via 
interactions with NFκB signalling (Wang et al., 2016). In this study, HG conditions promoted the 
activation and translocation of NFκB, with BA exerting its effect via blocking the translocation of 
NFκBp65 into the nucleus, thus inhibiting the promotion of inflammation. 
Betulinic acid and UCP2 
Betulinic acid’s effect on the uncoupling response is not well researched. Heiss et al., (2014) 
published a glycolytic switch study, in which they demonstrated the upregulations of UCP1 
and 2 by BA in the mouse embryonic fibroblast (MEF) cell line. The authors, however, 
suggested that future studies are warranted to test UCP2 expression in other cell types as UCP2 
is expressed differentially in different tissues. They further mentioned that the molecular 
mechanism behind UCP induction by BA is still to be elucidated (Heiss et al., 2014).   
Betulinic acid and NRF2 
Links between triterpenoids and NRF2 have previously been explored. Loboda et al., (2012) indicated  
that triterpenoids are able to regulate NRF2 via oxidative modification of -SH groups and signalling 
pathway phosphorylation (Loboda et al., 2012). Reisman et al., (2009) concluded that oleanolic acid, a 
triterpenoid like BA, protects against hepatoxicity via induction of NRF2 and its downstream targets 
(Reisman et al., 2009). 
Antioxidant properties 
The AO properties of BA have been researched, though not as comprehensively as BA’s other 
pharmacological properties. In rat models, BA had a protective effect against redox imbalance (Adeleke 
and Adaramoye, 2017). More relevantly, Yi et al. (2014) confirmed BA’s stimulation of the AO system 
(SOD2, GPx1, GSH) in response to alcohol-induced hepatotoxicity (Yi et al., 2014). Furthermore, 
Szuster-Ciesielska and Kandefer-Szerszen. (2005) proved, in a HepG2 cell model, that BA prevents 
excess superoxide production against ethanol-induced cytotoxicity. Szuster-Ciesielska and Kandefer-
Szerszen. (2005) also confirmed that the AO activity of BA and other triterpenes was dependent on 
ROS induction (Szuster-Ciesielska and Kandefer-Szerszeñ, 2005). Thus, taking into account BA’s 





Figure 2.9: The various effects of PGC1α (prepared by author). 
2.18) The human hepatoma cell line 
The liver, possessing insulin-requiring tissue, plays a central role in energy homeostasis with regards to 
the regulation of carbohydrate and lipid metabolism, and is often deemed the metabolic hub of the body 
(Rui, 2011). Following a meal, glucose, lipid and protein are shunted primarily to the liver via the portal 
circulation. Within the liver, AKT insulin signalling occurs, resulting in various outcomes such as 
glycogenesis, and excess glycolysis and amino acid degradation fuel fatty acid (FA) synthesis. During 
starvation, the liver is the primary site of glycogenolysis and gluconeogenesis, helping in the 
maintenance of normal blood glucose (Rui, 2011). The liver is also central to diabetic pathophysiology, 
in that high levels of gluconeogenic precursors, like glycerol and lactate, fuel a drastic increase in 
gluconeogenesis, which plays a primary role in hyperglycaemia associated with T2DM (Consoli, 1992).  
Primary hepatocytes, however, are rarely accessible for experimental culture models, possessing an 
unstable phenotype, and can only be cultured for a short time span (Shulman and Nahmias, 2012). 
HepG2 cells are an easily accessible, immortal cell line, whose characteristics have been thoroughly 
examined, possessing a stable phenotype, revealing many differentiated hepatic functions.  Donato et 
al. (2015) described their functions as follows: cholesterol/triglyceride metabolism, glycogen synthesis, 
lipoprotein metabolism, insulin signalling, amongst others (Donato et al., 2015). Further, studies 
comparing HepG2 cells and primary hepatocytes show that, despite being a cancer cell line, the HepG2 
cell line closely mimics the in vivo situation with regards to glucose metabolism (Sefried et al., 2018). 
However, this in vitro model does not mimic all the metabolic processes that are present in the in vivo 
state. Additionally, Kamalian et al. (2015) concluded that HepG2 cells are a suitable cell line to detect 
toxicity levels at different glucose concentrations (Kamalian et al., 2015). 
Furthermore, HepG2 cells also demonstrate high expression of AO systems and are therefore, suitable 
for evaluating stress response (Mersch-Sundermann et al., 2004).  The HepG2 cell line has been proven 
to accurately detect early changes in ETC via ATP measurement, which  is indicative of respiration and  
mitochondrial metabolic state (Kamalian et al., 2015). Thus, the easy to handle HepG2 cell line 
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possesses an advantageous phenotype for this study, given its abilities in detecting glucose toxicity and 

























CHAPTER 3: METHODS AND MATERIALS 
3.1) Materials 
Human hepatoma cells (HepG2) were obtained from the American Type Culture Collection (ATCC; 
HB-8065). Betulinic acid (B8936) and glucose (G8270-100G) was purchased from Sigma-Aldrich (St 
Louis, MO, USA). Western blotting reagents were obtained from Bio-Rad (Hercules, CA, USA). 
Antibodies were purchased from Cell Signalling Technology (Danvers, MA, USA), Abcam 
(Cambridge, UK), Sigma-Aldrich (St Louis, MO, USA) and Santa Cruz (Dallas, TX, USA). All other 
consumables and reagents were purchased from Merck (Darmstadt, Germany) unless otherwise stated. 
3.2) Preparation of Betulinic Acid 
Betulinic acid (5mM) stock solution was prepared in 0.1M phosphate buffered saline (PBS) and diluted 
in glucose-free-Eagles minimum essential medium (EMEM) to concentrations between 0-150µM for 
the MTT assay, and 5µM, 10µM, 25µM, 50µM for all remaining assays. 
3.3) Cell Culture 
The HepG2 cell line is an adherent cell line with an epithelial-like morphology. HepG2 cells are proven 
to demonstrate many differentiated hepatic functions as well as the ability to detect toxicity at various 
glucose levels (Donato et al., 2015, Kamalian et al., 2015).  
HepG2 cells were cultured (ethics number: BREC/00000822/2019) in monolayer in a 25cm3 cell culture 
flask at 37ºC with 5% CO2 in glucose-free Dulbecco’s Modified Eagle’s Medium (DMEM). Cells were 
washed with 0,1M PBS on alternate days and thereafter reconstituted with 5ml media. 
Glucose free DMEM (Thermo-Fisher, A1443001) was supplemented as follows: 
Normal Glucose (NG) media: 5mM glucose, 10% foetal calf serum (FCS), 1mM sodium pyruvate, 1% 
penstrepfungizone, 5mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES). 
High glucose (HG) media: 25mM glucose, 1mM sodium pyruvate, 1% penstrepfungizone, 10%FCS 








3.4) Cell Preparation for assays 
HepG2 cells were grown in complete culture media (CCM) and switched to respective HG and NG 
media at 80% confluency. Cells were then treated with varying BA concentrations and incubated 
[24hours (hrs), 37ºC]. Thereafter, cells were removed via trypsinization and mechanical agitation. The 
trypan blue exclusion method was employed for cell counting. Cell numbers differ per assay. All assays 
were performed twice separately with a minimum of three replicates unless specifically stated 
otherwise. 
3.5) Metabolic Activity 
3.5.1) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
Principle 
The MTT assay is a colorimetric assay used to determine cell viability. It is based on the principle by 
which metabolically active cells reduce the  yellow MTT salt to insoluble purple formazan crystals 
(Morgan, 1998). The crystals are then solubilised using dimethyl sulfoxide (DMSO), with the intensity 
of the purple formazan product being quantified using spectrophotometry (Fig. 3.1).  
The reduction requires the use of NADH as a cofactor and succinate dehydrogenase as an enzyme. The 
NADH cofactor is a by-product of the TCA cycle and the enzyme required forms complex 2 of the 
ETC. Thus formazan intensity is a direct indication of the metabolic state of the mitochondria and cell 
viability (Riss et al., 2016, Morgan, 1998)(Fig 3.1). 
Protocol 
HepG2 cells were seeded into 96 well plate (15,000 cells/well) and allowed to adhere overnight. 
Thereafter, cells were treated with varying concentrations of BA (0µM, 30µM, 50µM, 70µM, 90µM, 
110µM, 130µM, 150µM) under NG and HG conditions at 37°C for 24 hrs. Following treatment, cells 
were rinsed twice with 0.1M PBS and incubated (37°C, 4hrs) with 20µl MTT salt solution (5mg/ml in 
0.1M PBS) and 100µl EMEM.  Subsequently, supernatants were removed and 100 µl per well DMSO 
was added to solubilise the formazan (1 hr; 37°C). Optical density was measured at 570nm and a 
reference wavelength of 690nm using a spectrophotometer (Bio-Tek µQuant). Thereafter, the results 





Figure 3.1: Reduction of MTT salt utilising ETC component and TCA by-products (prepared by author). 
3.5.2) ATP assay 
Principle 
The metabolic state of the cell is driven by energy in the form of ATP. This ‘molecular energy currency’ 
is obtained from glycolysis as well as substrate level phosphorylation, however, the main source of ATP 
is obtained from OXPHOS. Oxidative phosphorylation is driven by H+ flux via the ETC and is hence 
controlled via such means, making it an ideal assessment of the metabolic state of a cell (Souza et al., 
2011) .  
The ATP assay employs luminescence techniques to directly determine ATP concentration within a 
cell, as an extrapolation of cell viability.  The reagent lyses the cells, freeing the ATP, which, along 
with co-factors Mg2+ and molecular oxygen, mono-oxygenates introduced luciferin via luciferase 
activity. This generates a luminescent signal directly proportional to the amount of ATP, and hence 
metabolically active cells, present in culture (Riss et al., 2016). 
Protocol 
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, USA) was conducted. 
Following treatment, HepG2 cells (20, 000 cells/well in 0.1M PBS) were seeded into an opaque 96-
well microtiter plate in triplicate. 20µL CellTitler-Glo® reagent was added followed by incubation in 
the dark [30 minutes (min), room temperature (RT)] to allow the reaction to occur. Thereafter, 
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luminescence was measured on a Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, 
USA), and results are represented as relative light units (RLU). 
3.5.3) Lactate Dehydrogenase Assay 
Principle 
Hyperglycaemic-induced OS results in high lipid peroxidation, which directly damages the membrane. 
The cytotoxicity detection kit is based on quantifying cytoplasmic enzymes released into the 
supernatant by damaged cells. Lactate dehydrogenase is a stable cytoplasmic enzyme, found in all cells, 
that is released into the supernatant when membrane integrity is compromised (Kumar et al., 2018). 
Extracellular LDH levels are measured enzymatically in cell culture supernatant. In the first step, NAD+ 
is introduced into the supernatant, being reduced to NADH/H+, as a co-factor in the conversion of lactate 
to pyruvate. This reaction is catalysed by LDH. In the second step, an introduced catalyst known as 
diaphorase transfers an H/H+ from the NADH/H+ to the INT tetrazolium salt, reducing it to formazan 
(Kumar et al., 2018).  
Protocol 
LDH cytotoxicity detection kit (Roche, Manheim, Germany) was used to quantify LDH in cell culture 
supernatants following treatment as per the manufacturer’s instructions. Briefly, 100µl of supernatant 
was transferred to a 96 well microtitre plate in triplicate followed by 100µL of cytotoxicity detection 
reagent [catalyst (diaphorase/NAD), dye solution (INT/sodium lactate)]. Plates were then incubated for 
25 min at room temperature in the dark. Optical density was measured at a wavelength of 500nm 
(microplate reader-Bio-Tek µQuant).  
3.6) Oxidative Stress 
3.6.1) Endogenous ROS: 2′,7′-dichlorodihydrofluorescein-diacetate assay 
Principle 
This simple, sensitive, fluorometric assay quantifies intracellular ROS. Cells were exposed to the 
membrane permeable, non-fluorescent H2DCF-DA probe (Wan et al., 2005). Once it passively diffuses 
into the cell, it is deacetylated by cellular esterases to non-fluorescent 2’,7’-dichlorfluorescein (DCFH). 
This compound reacts with ROS, and undergoes a 2e- oxidation to form fluorescent H2DCF (Fig. 3.2). 
This fluorescence can be measured via many means (flow cytometry, luminometry, microscopy) and is 




Figure 3.2:  Formation of fluorescent DCF for ROS quantification (prepared by author). 
Protocol 
DCF working solution was made by dissolving 0,5 µL of H2DCF-DA in 25ml DMEM. Cells grown in 
a 25cm3 flask (50 000 cells) were centrifuged (400xg; 10 min; RT) to a pellet and incubated in DCF 
solution (200µL; 30 min; 37ºC). Centrifugation (400xg; 10 min; RT) ensured removal of stain and cells 
were washed twice in 200µL 0,1M PBS. Cells were then resuspended in 200µL 0,1M PBS and plated 
in triplicate (96 well opaque microtiter-plate; 50µL per well). A blank of only 0,1 M PBS was also 
plated in triplicate. 
Fluorescence was then measured using a ModulusTM microplate luminometer (Turner Biosystems, 
Sunnyvale, CA). A blue filter was used at an excitation wavelength of 503nm and an emission of 
529nm. Fluorescence was calculated by subtracting average fluorescence of blank from sample 
fluorescence. 
3.6.2) Lipid Peroxidation: Thiobarbituric acid reactive substances assay 
Principal 
The TBARS assay is utilised to quantify lipid peroxidation as an indication of oxidative damage due to 
ROS. The assay quantifies MDA, a by-product of lipid peroxidation, via conjugation with two 
molecules of thiobarbituric acid (TBA), to generate a pink chromogenic adduct which is 
spectrophotometrically measured (Fig. 3.3).  
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Reactive oxygen species interact with polyunsaturated fatty acids (PUFAs), removing their hydrogen 
bond, thus initiating the chain reaction that is lipid peroxidation (Fig. 3.3). Molecular rearrangement 
follows, forming a conjugated diene. This then reacts with oxygen forming a lipid peroxy-radical which 
then removes H-bonds from new lipids, restarting the process. Nonradical products can be generated 
via AO H-atom donation to lipid peroxy-radicals (Devasagayam et al., 2003). 
High temperature and low pH conditions are required for this assay. Phosphoric Acid ensures an acidic 
environment while butyl-4-hydroxybenzoic acid (BHT) prevents non-specific chromophore formation. 
Butanol is used to extract the MDA-TBA from the sample allowing measurement of  the adducts (Grotto 
et al., 2009). 
 
Figure 3.3: TBARS assay reaction. 2TBA reacts with lipid peroxidation by-product malondialdehyde 
to produce chromophore measured at 532nm (prepared by author). 
Protocol 
200µl of supernatants from controls and BA-treated cells were added to test tubes, bar the negative and 
positive controls. 200µl of 2% H2PO4 and 200µL of 7% H2PO4 were added into each tube. 400µL 
TBA/butylated hydroxytoluene (BHT) was then added into all tubes except the negative control to 
which 400 µL of 3M HCl was added.  All tubes were then vortexed. 200µl 1M HCl was added to adjust 
the pH and 1µL MDA was added to the positive control. Thereafter, samples were boiled (15 min, 
100°C) and allowed to cool to RT. Butanol (1.5ml) was added to each sample, vortexed (30 sec) and 
allowed to stand, thus separating into different phases. 100µl of the upper butanol phase was removed 
and plated into a 96 well microtiter plate in five replicates.  Thereafter, the optical density was measured 
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at 532nm (reference wavelength: 600nm) using a spectrophotometer (Bio-tek µQuant). MDA 
concentration was calculated using the equation below (equation 3.1) (Devasagayam et al., 2003). 
3.6.3) Protein Carbonyl Assay 
Principle 
Quantification of intracellular carbonyl groups allows us to measure protein oxidation as a result of 
oxidative stress. Protein carbonylation is defined as the introduction of aldehyde or ketone carbonyl 
groups into a protein’s molecular structure (Purdel et al., 2014). This can be achieved via many 
mechanisms, including oxidation directly on specific amino acid residues within a protein chain, 
interaction between lipid peroxide products and aldehyde groups and interaction between carbonyl 
groups formed via lipid degradation or glycoxidation. The above-mentioned mechanisms are signs of 
oxidative stress, hence, high protein carbonyl content is a biomarker of oxidative stress (Purdel et al., 
2014). 
The process of carbonylation is irreversible, thus making it an ideal, accurate measurement for oxidative 
stress damage. The standard method for assessing protein carbonylation status involves 
spectrophotometry. Trichloroacetic acid is used to precipitate protein. Ethanol-ethyl acetate eliminates 
dinitrophenylhydrazine (DNPH) traces and solubilizes residual lipids. Centrifugation is utilised to 
remove any insoluble material. Carbonyl groups are derivatized with DNPH in order to obtain a DNP-
derived protein, which is a yellow colour. This products optical density can be measured at 370nm 
(Purdel et al., 2014) (Fig. 3.4) . 
Equation 3.1: Calculation to determine the MDA concentration (in mM), where 156mM-1 is the extinction 





Protein was isolated using Cell Lysis Buffer (200µL), quantified using the BCA assay, and standardized 
using cell lysis buffer once again. Standardized proteins were aliquoted into 15ml centrifuge tubes 
(100µL), along with 400µL of DNPH, and incubated (RT; 1 hr). Samples were vortexed every 15 
minutes. 100 µL of control treatment was added to 400µL 2,5HCl to act as a blank. Following this, 
500µL of 20% trichloroacetic acid was added to all samples and vortexed. Tubes were placed on ice for 
10 minutes, vortexed, and thereafter centrifuged (2000xg;10 min; RT). Protein precipitates were 
collected and supernatant discarded. Pellets washed (500µL 10% trichloroacetic acid), vortexed and 
centrifuged (2000xg; 10min; RT). Pellets were thereafter washed twice in 500µL ethyl acetate and final 
precipitates dissolved in 250µL 6M Guanidine hydrochloride. Incubation (37ºC;10 min) followed by 
removal of insoluble material via centrifugation (2000xg;10 min; RT) ensued. Supernatants were plated 
(50µL; triplicate) in a 96 well plate, and absorbance was measured at 370nm, spectrophotometrically. 
Carbonyl content was calculated using equation below ( Equation 3.2) (Mercier et al., 2004) 
 
Equation 3.2: Equation to determine protein carbonyl concentration in µM where 1cm is the pathlength 
and 22 000M-1cm-1 is the extinction coefficient of the DNP (Mercier et al., 2004). 




3.7) Antioxidant detection 
3.7.1) GSH Assay 
 
Figure 3.5: The GSH cycle (prepared by author). 
Principle 
Glutathione is an AO that exists in two states, namely GSH [glutathione (reduced)] and GSSG 
[Glutathione (oxidized)]. GSH donates an e- and, in a reaction catalysed by the enzyme glutathione 
peroxidase (GPx1), detoxifies H2O2 into H2O. It is thus oxidised to GSSG by doing so. Glutathione 
reductase (GR), with cofactor NADPH, reduces GSSG back to GSH. Glucose-6-phosphate 
dehydrogenase (G6PD) is an enzyme which reduces NADP+ to NADH, thus providing cofactors for 
GR action. Thus, the cycle ensues, detoxifying ROS (Fig. 3.5). High levels of GSH thus gives an 
indication to a sample’s AO ability (Rahman et al., 2006). 
The GSH-Glo® Glutathione Assay is a luminometric assay that detects and quantifies reduced 
glutathione as an indicator of AO response and capacity. Introduced luciferin derivative interacts with 
endogenous GSH, catalysed by GST, to generate luciferin which, via the action of luciferase, produces 
a light photon. This is quantified via luminometry and is directly proportional to intracellular GSH 
concentration (Fig. 3.6) (Rahman et al., 2006).  




The GSH-Glo® Glutathione Assay (Promega, Madison, USA) was conducted to assess AO ability. 
Following treatment, HepG2 cells (20,000 cells in 0.1M PBS) were plated into a 96-well opaque 
microtiter plate in triplicate.  Standards were prepared from 5mM GSH stock (0µM, 1µM, 2µM, 2,5µM, 
3µM, 4µM, 5µM) via dilution of de-ionized water and plated in triplicate. 50µL GSH-Glo® reagent 
was added followed by incubation in the dark (30 min, RT). 100 µL of Luciferin Detection Reagent 
was added to each well followed by 15 min incubation (RT). Thereafter luminescence was measured 
on a Modulus™ microplate luminometer. The standards helped construct a standard curve upon which 
the GSH-concentration of the sample was extrapolated. 
3.8) Protein isolation, quantification and standardization 
Principle 
Protein lysate from HepG2 cells was required for western blotting. Crude protein concentrations were 
quantified and standardized to the sample with the lowest concentration to ensure that samples could 
be compared accurately. Isolation occurred on ice to prevent protein degradation. Both chemical and 
mechanical lysis methods were utilised (Huang et al., 2010b). 
Protein concentration was quantified using the sensitive bicinchoninic acid assay (BCA). This assay 
was undertaken in alkaline conditions and relies on two reactions based on the biuret reaction. Cu2+ 
reacts with peptide bonds and is reduced to Cu1+. Cuprous ions then engage in chelation with 2BCA 
generating a purple colour. Colour intensity is directly proportional to protein concentration (Fig. 3.7). 
Spectrophotometric analysis ensues. A range of standards are generated from protein of known 
concentration. A standard curve is generated from these results and the sample protein concentration 





Figure 3.7: Biuret based BCA reaction to quantify protein (prepared by author). 
Protocol 
Protein samples were isolated using Cytobuster (250µL) lysis reagent (Novagen, USA, catalogue no. 
71009) supplemented with protease and phosphatase inhibitors (Roche, 05892791001 and 
04906837001, respectively) for western blotting. Adhered cells were incubated on ice (30 min) in 
Cytobuster and then mechanically scraped to facilitate cell lysis. Proteins were then transferred into 
micro-centrifuge tubes and subject to centrifugation (10 000xg; 4ºC; 10 min). Newly obtained crude 
protein was quantified using the BCA assay. Standards of known protein bovine serum albumin (BSA) 
were prepared (0mg/ml, 0,2mg/ml, 0,4mg/ml, 0,6mg/ml, 0,8mg/ml, 1mg/ml) and plated in triplicate 
alongside protein samples plated in duplicate (25 µL). 200µL BCA working solution (198µL 2BCA; 
4µL CuSO4) was added to each well followed by incubation (37ºC; 30 min). Optical density was 
measured spectrophotometrically (Bio-Tek µQuant) at 562nm. Absorbance values of standards were 
used to construct a standard curve and sample concentrations were extrapolated. Quantified proteins for 




3.9) Protein expression: Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Western Blotting. 
Principle 
SDS-PAGE and western blotting are widely used techniques to identify and detect protein expression. 
Proteins are subject to an electric field, separating them based on molecular weight, electro-transferred 
to a membrane, and immuno-detected (Kurien and Scofield, 2006). 
Standardized proteins are boiled (5 min; 100ºC) in 1x Laemmli buffer [Tris-Cl (6.8 pH), glycerol, 
Bromophenol blue, β-mercaptoethanol, SDS, dH2O]. These components allow for the efficient 
migration of protein samples through the gel. Bromophenol Blue is used as a tracking dye for 
visualization of protein migration;  β-mercaptoethanol is a reducing agent which breaks disulphide 
bonds, thus allowing for protein unfolding; Tris-HCl acts as buffer, maintaining pH during 
electrophoresis;  SDS provides an  overall negative charge to the proteins allowing it to be separated 
according to size rather than its shape and charge; and glycerol adds density to the sample, ensuring 
that it forms a thin layer in the wells during SDS-PAGE. Heating denatures the higher order of the 
protein. This ensures that the anionic charge is not neutralized to allow for protein movement within an 
electric field (Mahmood and Yang, 2012).  
Proteins were separated using SDS-PAGE. SDS-PAGE involves the migration of molecules through a 
gel, under the influence of an electric field, with the negatively charged proteins migrating towards the 
positively charged cathode. Laemmli buffer ensured that all proteins were in their primary form. Smaller 
proteins migrate faster and further (towards the cathode) than larger ones. The frictional coefficient is 
also dependant on the viscosity of buffer and pore size of the medium (Mahmood and Yang, 2012). 
A polyacrylamide gel, a cross linked polymer of acrylamide and N, N’-methylene bis-acrylamide, is 
used along with Tetramethylethylenediamine (TEMED) (free radical stabilizer) and ammonium 
persulphate (free radical donor) to ensure polymerisation. Two types of gels are used in SDS-PAGE: a 
high percentage resolving gel allowing for accurate size separation and a low percentage stacking gel 
above this, ensuring that all proteins start at the exact same line, before the electric field is applied. For 
efficient separation, constant temperature must be maintained (to prevent denaturing) and convection 
currents must be avoided. Tris maintains running pH of run and glycine ensures proteins move in a tight 
band and that none straggle (Mahmood and Yang, 2012). 
Following SDS-PAGE, proteins are electro-transferred from a gel to a nitrocellulose membrane. 
Nitrocellulose membranes possess high binding capacity for protein, are easily stained for protein and 
do not require pre-activation (Kurien and Scofield, 2006).  
An electric field was utilised to elute protein from the gels, transferring them to membranes. The 
membranes, fibre pads and the gels were equilibrated in transfer buffer. Equilibration helps to reduce 
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the amount of SDS and other buffer salts in the gel, which can interfere with protein adsorption to 
the membrane. The gel and membrane were then sandwiched by fibre pads on either side between two 
electrodes, allowing uniform transfer. The blot transfer system then applied a voltage, generating an 
electric current perpendicular to the gel surface. This allowed negatively charged proteins to migrate 
from the gel onto the nitrocellulose membrane (Kurien and Scofield, 2006). 
Protein expression was then detected using immunological and chemiluminescent methods. A primary 
antibody specific to the protein of interest is added to the membrane followed by an enzyme [horse 
radish peroxidase (HRP)]-conjugated secondary antibody that binds to the primary antibody. A 
chemiluminescent reagent is added, reacting with the enzyme, releasing a luminescent signal directly 
proportional to protein intensity, allowing for detection (Fig. 3.8) (Kurien and Scofield, 2006). 
 
Figure 3.8: Immunoblotting concept employed in western blotting to detect protein levels (prepared by 
author). 
Protocol 
Standardized proteins were boiled (100°C) in Laemmli buffer [0.5M Tris-Cl (6.8 pH), glycerol, 1% 
Bromophenol blue, 5% β-mercaptoethanol, 10% SDS, dH2O] for 5 minutes. Thereafter, gel 
electrophoresis was used to separate proteins according to molecular weight (4% stacking gel; 10% 
resolving gel) at 150V for 1 hr (Bio-Rad Mini PROTEAN Tetra-Cell System). This was followed by 
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electro-transference to a nitrocellulose membrane. The stacking gel was discarded and the resolving gel 
was carefully removed from the glass plate. Gels, fibre pads and membranes were soaked in transfer 
buffer (20% methanol, 25mM Tris, 192mM glycine for 10 min) and sandwiched together. The sandwich 
was placed between electrodes and subject to a current (30 min; 20V) using the Transblot Turbo 
Transfer System, (Bio-Rad). Membranes were blocked using 5% BSA in Tris buffered saline containing 
Tween 20 (TTBS: 137mM NaCl, 24mM Tris, 0.5% Tween 20, 2.7mM KCl). Membranes were 
incubated with primary antibodies (Table 3.1) overnight at 4ºC. The membranes were then washed with 
TTBS, probed with a HRP-conjugated secondary antibody (Table 3.1), incubated (2 hrs, RT, 1:5 000) 
and viewed. Membranes were developed using 400µl BioRad Clarity Western ECL Substrate (Bio-Rad, 
Hercules, USA) and the ChemiDoc XRS+ Molecular Imaging System (Bio-Rad) was used to visualize 
protein bands. Membranes were stripped via incubation with 5% hydrogen peroxide (37°C, RT). Protein 
expression was normalised against HRP-conjugated β-actin. Results were displayed as Relative Band 
Density (RBD) of relevant proteins divided by the RBD of β-actin. 
Table 3.1: Antibodies and dilutions utilised for western blotting (prepared by author). 
PRIMARY 
ANTIBODY 
CATALOGUE NO. DILUTION 
Anti-pNRF2 ab76026 (Abcam) 1:1000 in 5% BSA 
Anti-NRF2 ab31163 (Abcam) 1:1000 in 5% BSA 
Anti-SOD2 HPA001814 (Sigma-
Aldrich) 
1:1000 in 5% BSA 
Anti-CAT C0979 (Sigma- 
Aldrich) 
1:1000 in 5% BSA 
Anti-SIRT3 C73E3 (Cell signalling 
technologies) 
1:1000 in 5% BSA 
Anti-Lon-P1 HPA002034 
(Sigma-Aldrich) 
1:1000 in 5% BSA 
Anti-IRβ ab10321 (Abcam) 1:2000 in 3% BSA 
Anti-PGC1α ab72230 (Abcam) 1:1000 in 5% BSA 
Anti-UCP2 ab67241 (Abcam) 1:1000 in 5% BSA 
Anti-PPARγ ab59256 (Abcam) 1:1000 in 5% BSA 
Anti-NFκB  D14E12 (Cell 
signalling) 
1:1000 in 5% BSA 
Anti-β-actin A3854 (Sigma-
Aldrich) 
1:5 000 in 5% BSA 
SECONDARY 
ANTIBODY 
CATALOGUE NO. DILUTION 
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Goat Anti-mouse IgG 
HRP 
Sc-2005 (Santa Cruz) 1:5 000 in 5% BSA 
Goat Anti-rabbit IgG 
HRP 
Sc-2004 (Santa Cruz) 1:5 000 in 5% BSA 
Donkey anti-goat IgG-
HRP: 
Sc-2020 (Santa Cruz) 1:5 000 in 5% BSA  
 
3.10) Messenger RNA quantification: Quantitative Polymerase Chain Reaction 
Principle 
PCR allows for a sensitive, specific and reproducible method to amplify a specific DNA sequence from 
a template strand. This method enables copies of a DNA template to be made in direct proportion to 
original amount of target DNA. qPCR simultaneously amplifies and quantifies target DNA. Fluorescent 
dyes bind to double stranded DNA (dsDNA), emitting fluorescence when bound, thus when DNA is 
produced the fluorescent  signal is  amplified and quantified (Pestana et al., 2010). 
There are 3 steps in the PCR process (Arya et al., 2005). The initial step involves exposing the DNA 
template to extreme temperatures (94-98ºC) for 20-30 seconds, resulting in denaturation. The H-bonds 
between dsDNA are broken producing single stranded DNA (ssDNA) which serves as the template 
DNA strand. Thereafter, temperatures are lowered to 55-60ºC and two synthesized oligonucleotide 
primers (forward and reverse) complimentary to the sites adjacent to the target region, are annealed to 
the template DNA via complimentary base pairing. During extension, the temperature is increased to 
72ºC (optimum temperature for Taq polymerase activity) and Taq polymerase facilitates the attachment 
of deoxynucleoside triphosphates (dNTPs) complimentary to the ssDNA at the target gene, resulting in 
a new dsDNA. MgCl2 is a co-factor for Taq Polymerase and is required for primer binding to template 
DNA (Fig. 3.9). The buffer solution used maintains the pH and ionic strength of the reaction solution 
suitable for activity of Taq polymerase. The process is repeated for 30-40 cycles to ensure sufficient 
amplification (Arya et al., 2005). 
Housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was run alongside samples 
in each run. The amount of target DNA is reported relative to the amount of housekeeping gene for 
every sample. Housekeeping genes are used because they are expressed constantly, regardless of tissue, 
at all stages of development, and hence expression levels should remain constant amongst samples 
(Arya et al., 2005). 
In order to measure mRNA expression, RNA is isolated and reverse transcribed into complementary 
DNA (cDNA) which serves as the starting DNA template in qPCR. RNA isolation utilises Qiazol 
reagent (containing phenol), which degrades cellular and nuclear membranes, while maintaining the 
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integrity of RNA; chloroform, which removes DNA, protein, and lipids; isopropanol, which precipitates 
the RNA;  and nuclease free water (nfH2O) , which lacks RNase enzymes allowing the RNA to be 
dissolved while preventing its degradation (Arya et al., 2005).  
 
Figure 3.9: 3 steps involved in a single PCR cycle resulting in DNA amplification (prepared by author). 
Protocol 
Following treatment, HepG2 cells were washed three times in 0.1M PBS; and subsequently incubated 
in 500µL Qiazol (Qiagen, Hilden, Germany) and 500µL 0,1M PBS (5 min, RT). Cells were 
mechanically lysed using a cell scraper and lysates were transferred to 2ml micro-centrifuge tubes and 
stored overnight at -80ºC. Thereafter, samples were thawed, chloroform (100µL) was added and the 
samples were centrifuged (12,000xg; 4ºC; 15 min). Supernatants were transferred to fresh 2ml micro-
centrifuge tubes and 250µL cold isopropanol was added before overnight storage at -80ºC. 
Following incubation, samples were thawed and centrifuged (12,000xg; 4ºC; 20 min). Supernatants 
were removed, RNA pellets were washed in 75% cold ethanol (500µl), and centrifuged (7,400xg; 4ºC; 
15 min). The ethanol was removed and the RNA samples were air dried for 10 min at RT. RNA pellets 
were then resuspended in 15µL of nfH2O and quantified using the Nanodrop2000 spectrophotometer 
(Thermo-Fischer Scientific).  
The A260/280 ratio was used to assess RNA purity. RNA was then standardized to 1,000 ng/µl and 
reverse transcribed into cDNA using the Maxima H Minus First Strand cDNA synthesis Kit (Thermo-
Fisher Scientific; K1652) as per manufacturer’s instructions.  Briefly, a master mix comprising of 1µL 
RNA, 0,25µL Oligo(dt) primer; 1µL 10mm DNTP mix; 12,75µL nfH2O was incubated at 65ºC for 5 
min in the thermocycler (Bio Rad T100TM Thermal Cycler).  Thereafter, 4µL 5X RT Buffer and 1µL 
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Maxima H minus enzyme was added to each sample and incubated (10 min at 25ºC; 15 min at 50ºC; 5 
min at 85ºC). 60µL nfH2O was added to each sample and stored at -80ºC. 
Gene expression was analysed according to the manufacturer’s instructions using PowerUp SYBR 
Green Master Mix (Thermo-Fisher Scientific; A25779). Forward and reverse primers of genes of 
interest (Table 3.2) were diluted down to 25µM with nfH2O. Samples were plated (1µL) with 9µL of 
mastermix (5µL SYBR Green; 1µL Forward Primer; 1µL Reverse Primer; 2µL nfH2O) in triplicate. 
GAPDH was used as the housekeeping gene to normalise gene expression. 
Sample amplification was performed using the CFX96 TouchTM Real-Time PCR Detection System 
(Bio-Rad). Initial denaturation (95ºC; 8 min) was followed by 37 denaturation cycles (95ºC; 15 sec), 
annealing (40 sec; temperatures) and extension (72ºC; 30 sec). Calculation demonstrated by Livak and 
Schmittgen (2001) was used to determine mRNA expression variances. Results are expressed as fold 
change relative to the control (GAPDH) (Livak and Schmittgen, 2001). 
With regards to miRNA, RNA, standardized to 1,000 ng/µl, was reverse transcribed into cDNA using 
the miScript II RT Kit (Qiagen, 218161) as per manufacturer’s instructions.  Briefly, a master mix, 
comprising of 1µL RNA, 4µL 5x miScript HiFlex Buffer, 2µL 10x miScript Nucleics Mix , 11µL 
RNAse free H2O, 2µL miScript Reverse Transcriptase Mix, was incubated at 37ºC for 60 min, 95ºC for 
5 min and 4ºC for 5 min.  
MiRNA cDNA was used to determine miR-124 expression using the miScript SYBR Green PCR Kit 
(Qiagen, 218073). Human RNU6 (Qiagen, MS000033740) was used as a house keeping gene. Each 
reaction was carried out in triplicate containing 2X Quantitect SYBR Green (6.25 µl), 10X miScript 
Universal Primer (1.25 µl), RNase free water (2.25 µl) and template cDNA (1 µl). The qPCR 
experiments were conducted in the CFX Touch™Real Time PCR Detection System (Bio-Rad) at the 
following thermal conditions: Initial denaturation (95ºC; 15 min) was followed by 37 denaturation 
cycles (94ºC; 15 sec), annealing (40 sec; 55ºC) and extension (70ºC; 30 sec).  . The cycle threshold (Ct) 
values were used to analyse changes in miRNA expression and were represented as fold change relative 
to the house keeping gene RNU6 using the method described by Livak and Schmittgen (2001) (Livak 











GPx1 57.4ºC F-5’-GACTACACCCAGATGAACGAGC-3’ 
R-5’-CCCACCAGGAACTTCTCAAAG-3’ 
PGC1α 57.6ºC F-5’-CCAAACCAACAACTTTATCTCTTCC-3’ 
R-5’-CACACTTAAGGTGCGTTCAATAGTC-3’ 
SIRT3 57ºC F-5’-CGGCTCTACACGCAGAACATC-3’ 
R-5’-CAGC GGCT CCCC AAAG GAAC AC-3 
NRF2 58ºC F-5’ AGTGGATCTGCCAACTACTC 3’ 
R-5’ CATCTACAAACGGGAATGTCTG- 3’ 
GAPDH variable F-5’-TCCACCACCCTGTTGCTGTA-3’ 
R-5’-ACCACAGTCCATGCCATCAC-3’ 
 
3.11. Statistical Analysis 
Data analysis was performed using the One-way Analysis of Variance (ANOVA) and Bonferroni test 












CHAPTER 4: RESULTS 
4.1) Betulinic acid stabilises mitochondrial output and maintains cell viability 
The intracellular energy and metabolism status of BA-treated HepG2 cells were assessed by the MTT 
and ATP assays. 
Betulinic acid is a known anti-cancer agent, and hence non-toxic and low concentrations of BA were 
used to establish its antioxidant and anti-hyperglycaemic properties (Yogeeswari and Sriram, 2005). 
Both the MTT and ATP assays measured cell viability and metabolic output.  
An MTT assay confirmed that BA (0-150µM) did not significantly impair cell viability and energy 
output of the HepG2 cell line under NG conditions (Fig. 4.1A) and HG conditions (Fig. 4.1B). No 
significance was expressed relative to the controls. 
In literature, it was found that BA concentrations higher than 21µM exhibit a degree of toxic 
potential, hence values within the MTT range, but below 21µM were chosen (Fu et al., 2005, Santos 
et al., 2009). ATP cell viability assays were conducted on 5µM and 10µM treatments as a preliminary 
measure to determine mitochondrial function. No significant differences were observed in ATP levels 



























































































Figure 4.1: MTT assay demonstrating cell viability and constant levels of metabolic activity 
in both A) normoglycaemic and B) hyperglycaemic media. ATP assay further demonstrating 
this at given concentrations in both C) normoglycaemic and D) hyperglycaemic media. 
















4.2) Betulinic acid reduces hyperglycaemic-induced toxicity. 
Hyperglycaemic conditions induce ROS, which can lead to peroxidation of the cell membrane 
(Collins et al., 2018). An LDH assay was run to ensure that BA exerted no cytotoxic effect on the cell 
line, and to assess if BA could combat the HG-induced toxicity. 
BA reduced HG-induced LDH levels optimally at 5µM (p<0.0001) and less so at 10µM 
(p<0.05), in comparison to HG negative control (Fig. 4.2B). Additionally, NG conditions 
showed no significant change in the LDH levels (Fig. 4.2A). 
Thus, BA reduced HG-induced membrane damage. It is noteworthy that LDH levels were 







































Figure 4.2: LDH quantified in the supernatants, in both A) normoglycaemic (p= 0,1390) and B) 













4.3) Betulinic acid enhances insulin receptor phosphorylation   
To preliminarily assess BA’s anti-hyperglycaemic effects on the HepG2 cell line at these specific 
concentrations, we tested a previously researched anti-diabetic scenario.  
Betulinic acid is known to enhance phosphorylation of the β subunit of the insulin receptor 
(Castellano et al., 2013). Recent studies, however, proved that HG conditions glycate the insulin 
receptor thus inhibiting binding (Rhinesmith et al., 2017). A PY20 western blot was performed to 
verify tyrosine residue phosphorylation. 
Betulinic acid promoted phosphorylation of IR at 5µM and 10µM (p<0.0001) under NG conditions 
(Fig. 4.3A) Under HG conditions (Fig. 4.3B), BA significantly upregulated IRβ phosphorylation at 
5µM (p<0.05). Interestingly, similar phosphorylation was observed between the insulin control and 
5µM HG conditions.  
Thus, it was established that, despite possible HG-induced glycation of the insulin receptor, BA, 
nonetheless, promoted IR phosphorylation at 5µM, similar to that of insulin. 
 






















Figure 4.3: PY20 western blot demonstrating phosphorylation of IRβ in A) normoglycaemic 
conditions (p=0.0004) and in B) hyperglycaemic (p< 0.0001) conditions. #p<0.05; ##p<0.001; 










4.4) Betulinic acid downregulates reactive oxygen species and its biomarkers 
Hyperglycaemic conditions promote ROS formation, with consequent lipid peroxidation and protein 
carbonylation (Nishikawa et al., 2000). The analysis of ROS utilized the DCF assay for endogenous 
ROS quantification, as well as the PCA and TBARs assay to measure protein carbonyls and lipid 
peroxides. 
Betulinic acid treatment reduced ROS levels in both HG (Fig. 4.4B) and NG (Fig. 4.4A) conditions, at 
both 5µM and 10µM concentrations (p<0.0001). This peculiar result suggests that BA reduced ROS 
even in the absence of HG induced OS. 
MDA is a lipid peroxidation by-product and high levels are associated with HG-induced OS (Asmat et 
al., 2016). Expectedly, BA induced a more pronounced (p<0.0001) downregulation of MDA at both 
concentrations of BA (Fig. 4.4D) in HG conditions. Normoglycaemic MDA levels demonstrated a 
subtle downregulation at 5µM (p<0.001) and 10µM (p<0.05) of BA (Fig. 4.4C).  
Lipid peroxidation by-products are able to post-translationally modify proteins, resulting in 
irreversible carbonylation (Hauck and Bernlohr, 2016). Further analysis via PCA revealed that BA 
treatment significantly (p<0.0001) downregulated carbonyl levels in HG media (Fig. 4.4F). Under NG 
conditions (Fig. 4.4E), BA decreased protein carbonyl levels less significantly (p<0.001). 
Taken together, these results suggest that BA downregulates ROS independent of OS-status, however 
BA understandably reduces OS markers (lipid peroxides and protein carbonyls) more in the toxic HG 
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Figure 4.4: The H2DCF-DA assay quantifying intracellular ROS levels in response to BA 
administration in a A) normoglycaemic (p<0.0001) and B) hyperglycaemic (p<0.0001) 
model. Lipid peroxidation by-product, MDA, quantified via a TBARS assay in both C) 
normoglycaemic (p=0.0037) and D) hyperglycaemic (p<0.0001) media. PCA assay 
quantifying protein carbonyl concentrations as an effect of ROS and lipid peroxidation, in E) 
normoglycaemic (p<0.0001) and F) hyperglycaemic (p<0.0001) media. #p<0.05; ##p<0.001; 





4.5) Betulinic acid promotes PPARγ/NRF2 positive feedback loop in hyperglycaemic 
conditions. 
Multiple studies have linked triterpenes and specifically BA, to AO-related transcription factors 
PPARγ and NRF2 (Loboda et al., 2012, Brusotti et al., 2017). These transcription factors transcribe 
for a variety of AOs. Both transcription factors additionally transcribe for each other, by generating a 
positive feedback loop, and thus potentiate the AO response (Lee, 2017). 
Betulinic acid treatment potentiated the expression of PPARγ, in both conditions and both 
concentrations. Under NG conditions (Fig. 4.5A), BA upregulated PPARγ (p<0.05)  in HepG2 cells; 
whilst under HG conditions (Fig. 4.5B) PPARγ was more significantly upregulated at 10µM BA 
(p<0.001) and optimally at 5µM BA (p<0.0001).  
The enhanced PPARγ levels in HG state coincides with its feedback partner, NRF2. BA potentiated 
NRF2 protein expression to maximum significance (p<0.0001) at both concentrations in HG 
conditions (Fig. 4.5D). BA also upregulated NRF2 mRNA levels in HG conditions (Fig. 4.5F) at 
10µM (p<0.05) and optimally at 5µM (p<0.0001). BA did not upregulated NRF2 gene (Fig. 4.5E) and 
protein (Fig. 4.5C) in NG conditions. 
Altogether, BA potentiated the AO-associated PPARγ/NRF2 feedback loop, at an optimal 































































































Figure 4.5: PPARγ protein expression in A) normoglycaemic (p=0.0047) and B) hyperglycaemic 
(p<0.0001) conditions. Protein expression of total NRF2 in C) normoglycaemic (p=0.0868) and D) 
hyperglycaemic (p<0.0001) conditions, along with mRNA levels of NRF2 in E) normoglycaemic 
(p=0.0019) and F) hyperglycaemic (p=0.0007) conditions. #p<0.05; ##p<0.001; ###p<0.0001 relative 




4.6) Epigenetic control of NRF’s phosphorylation 
Additionally, we explore miR124 as an epigenetic link between PPARγ and phosphorylation of 
NRF2. MiR124 is induced by PPARγ, and exerts its effect indirectly via signal pathways, 
phosphorylating NRF2 (Shu and Zhang, 2019, Wang et al., 2017). Phosphorylation of NRF2 results in 
activation and nuclear translocation. Multiple studies have also suggested that triterpenes 
phosphorylate NRF2 directly for AO actions (Loboda et al., 2012). 
Betulinic acid increased expression of miR124 (qPCR), at 5µM (p<0.05) in HG conditions (Fig. 
4.6B). Furthermore, protein expression of phosphorylated NRF2 was also upregulated at both BA 
treatments (p<0.0001) in HG conditions (Fig. 4.6D). Betulinic acid did not upregulate miR124 (Fig. 
4.6A) and pNRF2 (Fig. 4.6C) levels in NG media. 
Betulinic acid indirectly modulates miR124, which promotes phosphorylation of NRF2 at 5µM HG 



















































































Figure 4.6: qPCR for miRNA124 in A) normoglycaemic (p=0.0866) and B) hyperglycaemic 
(p=0.0093) conditions along with protein expression of pNRF2 in C) normoglycaemic 
(p=0.0116) and D) hyperglycaemic (p< 0.0001) conditions. #p<0.05; ##p<0.001; 












4.7) Betulinic acid upregulates the antioxidant mechanism in hyperglycaemic 
conditions. 
Enhanced PPARγ/NRF2 expression potentiates the AO response. Both transcription factors transcribe 
for CAT and SOD2, with NRF2 additionally transcribing for GPx1. SOD2 functions to detoxify 
superoxides into H2O2. This H2O2 is reduced into harmless H2O via two enzymes, CAT and GPx1. 
Furthermore, GPx1 utilises a non-enzymatic cofactor known as GSH (Noori, 2012).  
The optimal concentration of 5µM BA (HG conditions; Fig. 4.7B) upregulated SOD2 protein 
expression (p<0.0001) and CAT (p<0.05) expression (Fig. 4.7D). BA treatment in NG conditions had 
no effect on both these antioxidants (Fig. 4.7A; Fig. 4.7C). 
Further, BA upregulated the GPx1/GSH mechanism in the HG state. BA significantly upregulated 
GPx1 mRNA levels (p<0.0001) at both concentrations in HG media (Fig. 4.7F). Luminometry 
showed increased GSH levels at 5µM (p<0.001) and at 10µM (p<0.05) in HG conditions (Fig. 4.7H).  
Taken together, the 5µM BA optimal concentration enhanced expression of the 
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Figure 4.7: SOD2 protein levels in A) normoglycaemic (p<0.0001) and B) hyperglycaemic 
(p<0.0001) conditions. CAT protein levels in C) normoglycaemic (p= 0,0001) and D) hyperglycaemic 
(p=0.0003) conditions. GPx1 mRNA levels in E) normoglycaemic (p= 0,0028) and F) hyperglycaemic 
(P<0.0001) conditions. Luminometric quantification of reduced glutathione levels in G) 
normoglycaemic (p=0.0010) and H) hyperglycaemic (p=0.0003) conditions. #p<0.05; ##p<0.001; 






4.8) Betulinic acid modulates UCP2  
PPARγ transcribes for UCP2, which is upregulated in the HG condition, and combats ROS (Pierelli et 
al., 2017, Sosa-Gutiérrez et al., 2018, Liu et al., 2013). 
UCP2 protein levels were upregulated in HG media (Fig. 4.8B) at 5µM BA (p<0.05) treatment. 
Conversely, BA, in the absence of OS, in NG media (Fig. 4.8A), downregulated UCP2 at both 5µM 
(p<0.0001) and 10µM (p<0.001). This suggests differential regulation of UCP2 by BA based on the 



























Figure 4.8: Differential regulation of UCP2 protein expression by BA in A) normoglycaemic 
(p<0.0001) and B) hyperglycaemic (p<0.0001) conditions. #p<0.05; ##p<0.001; 















4.9) Betulinic acid differentially regulates NFκB  
Transcription factor NFκB promotes ROS-induced inflammation and ROS production (Sharma et al., 
2018, Morgan and Liu, 2011). Additionally, NFκB is involved in a wide range of cellular responses 
via gene induction (Zhang et al., 2017). Many proteins and genes in this study including PPARγ, 
PGC1α, miR124 and NRF2 have been linked to repression of NFκB, directly targeting NFκB p65 in 
inflammatory conditions (Wahli, 2008, Wang et al., 2017, Eisele et al., 2015, Wardyn et al., 2015). It 
was hypothesized that increased expression of these proteins in HG state would downregulate NFκB. 
Under HG conditions (Fig. 4.9B), BA markedly downregulated NFκB at both 5µM and 10 µM 
concentrations (p<0.0001). In contrast, upregulations of NFκB by BA at 5µM (p<0.001) and 10µM 
(p<0.0001) in non-inflammatory NG conditions suggest that BA differentially modulates NFκB to 
suit circumstances (Fig. 4.9A).  































































Figure 4.9: Protein expression of NFκB in A) normoglycaemic (p<0.0001) and B) 












4.10) Betulinic acid potentiates the SIRT3/PGC1α positive feedback loop 
SIRT3 is a mitochondrial deacetylase, which activates various AO-related proteins, including SOD2 
(Chen et al., 2011). NRF2, with the aid of its co-factor PGC1α, transcribes for SIRT3 (Song et al., 
2017). Additionally, PGC1α forms a positive feedback loop with SIRT3 (Kong et al., 2010). 
Furthermore, PGC1α is also involved in many aspects of AO regulation, responsible for upregulations 
in CAT, SOD2, and UCP2 amongst others (Valle et al., 2005). 
Betulinic acid elevated SIRT3 protein levels (p<0.0001) at both 5µM and 10 µM concentrations in 
HG conditions (Fig. 4.10B). Further qPCR revealed concomitant upregulations of SIRT3 mRNA 
levels at both 5µM (p<0.001) and 10µM (p<0.05) BA in HG conditions (Fig. 4.10D).  
PGC1α plays a role in AO induction. PGC1α protein levels were significantly upregulated (p<0.05) 
by 5µM BA HG conditions (Fig. 4.10F). Additionally, PGC1α mRNA levels were upregulated at both 
concentrations of BA in HG (Fig. 4.10H) conditions (p<0.0001).  
In NG conditions, both PGC1α at 10µM (p<0.0001) and SIRT3 (p<0.05) mRNA levels were 
upregulated (Fig. 4.10C; Fig. 4.10G), but their protein expressions were unchanged. 
Thus, concomitant upregulations at 5µM BA in HG conditions, between both SIRT3 and PGC1α, at 
an mRNA and protein level suggests that BA potentiates their positive feedback loop and validates the 
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Figure 4.10 SIRT3 protein expression in A) normoglycaemic (p=0.1120) and B) 
hyperglycaemic(p<0.0001) conditions. SIRT3 mRNA levels in C) normoglycaemic (p<0.0001) and D) 
hyperglycaemic conditions (p<0.0001). PGC1α protein levels in E) normoglycaemic (p=0.0002) and 
F) hyperglycaemic (p=0.0025) media. PGC1α mRNA levels in G) normoglycaemic (p=0.0005) and 





4.11) Betulinic acid promotes intramitochondrial degradation of oxidized proteins. 
An extension of SIRT3’s activities include its proven de-acetylation of LONP1 (Gibellini et al., 
2014). LONP1’s proteolytic digestive capabilities are vital to lower oxidized protein levels (Ngo et 
al., 2013).  
At the optimal 5µM BA concentration (HG conditions)(Fig. 4.11B), LONP1 protein expression was 
significantly upregulated (p<0.05). Additionally, LONP1 levels in NG (Fig. 4.11A) conditions 
demonstrated upregulation at 10µM BA (p<0.05). 
Thus, BA indirectly promoted LONP1 at an optimal concentration of 5µM BA in HG conditions to 



























Figure 4.11: LONP1 protein expression in A) normoglycaemic (p=0.0005) and B) 















CHAPTER 5: DISCUSSION 
Oxidative stress, a state of redox imbalance favouring pro-oxidants, is a common pathological 
mechanism observed in diabetic complications (Asmat et al., 2016). Re-establishing the AO response 
may help alleviate OS, thus reducing the risk of diabetic complications. In this study, BA’s 
established AO properties were extrapolated to the HG state, a good mimic of T2DM. It is of note, 
however, that despite its attempt to mimic the diabetic state, an in vitro model does, to some extent, 
eliminate normal human cellular and metabolic interactions from the equation. 
Loboda et al. (2012) previously concluded that triterpenoids are concentration dependant, displaying 
anticancer activities at high concentrations, and anti-inflammatory and cytoprotective activities at low 
concentrations (Loboda et al., 2012). Betulinic acid’s anticancer ability has been extensively 
researched. Fu et al. (2005) and Santos et al. (2009) established that BA exerts toxicity at 
concentrations ranging between 21µm and 36µm (Moghaddam et al., 2012, Fu et al., 2005, Santos et 
al., 2009). The MTT data in this study demonstrated no toxicity between 5µM and 150µM BA 
concentration (Fig. 4.1A; Fig. 4.1B). Thus, concentrations 5µM and 10µM were chosen for study, 
within the MTT range, but below the previously reported toxic levels. An ATP cell viability assay 
confirmed that both BA concentrations were non-toxic (Fig. 4.1C; Fig. 4.1D). 
Although commonly regarded as viability assays, the MTT and ATP assays alternatively reveal 
complementary information with regards to the metabolic state of the cell. MTT cofactor, NADH is a 
substrate for the ETC, and a by-product of the TCA cycle, which is an important process linking lipid, 
protein and glucose metabolism (Riss et al., 2016). Furthermore, complex 2 of the ETC, succinate 
dehydrogenase, is the principle enzyme required for MTT conversion (Morgan, 1998). The ETC is 
coupled to OXPHOS, an ATP generator. Therefore, the MTT assay is a good indicator of the status of 
the redox potential of the cell. Constant MTT and ATP readings observed in this study alluded to BA 
being involved in the maintenance of a stable intramitochondrial metabolic environment (Fig. 4.1). 
Due to BA’s implications in anti-cancer activity, an LDH assay was warranted to ensure that BA did 
not exert any membrane damage (Zhang et al., 2016, Sánchez-Quesada et al., 2013). Additionally, HG 
induced OS results in the peroxidation of lipid-membranes, which, we hypothesized, may be 
prevented by the activity of BA (Cheeseman, 1993). In the HG model, BA downregulated levels of 
LDH (Fig. 4.2B). The NG model showed no difference (Fig. 4.2A). Thus, the results of the assay can 
be considered a two-fold preliminary indication to both BA’s lack of toxicity, and possible presence 
of cytoprotective capacity to ROS-induced membrane damage. 
Betulinic acid’s anti-diabetic potential is well established (Brusotti et al., 2017, Castro et al., 2014, 
Castellano et al., 2013). A particular mechanism involves BA’s phosphorylation of the β subunit of 
the IR (Castellano et al., 2013). Rhinesmith et al. (2017), however, concluded that a method of insulin 
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resistance involves HG conditions directly glycating the receptor, inhibiting its binding (Rhinesmith et 
al., 2017). To ensure that BA at concentrations of 5µM and 10µM had a direct effect on the HepG2 
cell line, we tested this previously researched anti-diabetic scenario. Western blots of IRβ confirmed 
BA’s phosphorylation of IRβ in NG conditions at both 5µM and 10µM BA, and also in HG 
conditions at 5µM (Fig. 4.3). Betulinic acid phosphorylates the IR in HG conditions to a lesser extent, 
due to possible glycation of IR. This 5µM BA HG concentration, however, demonstrated no 
significance relative to the insulin control (Fig. 4.3B), implying that BA phosphorylates the IR to a 
similar degree as insulin in HG conditions. 
Phosphorylation of IR promotes insulin signalling pathways, resulting in GLUT4 membrane 
localization and resultant glucose uptake and disposal (Aronoff et al., 2004). Additionally, both 
PGC1α and PPARγ are proven to promote GLUT4 glucose uptake (Wu et al., 1998, Leick et al., 
2010). Significant upregulations of both these proteins at 5µM in HG conditions, alongside IRβ, 
implies increased glucose uptake (Fig. 4.3B; Fig. 4.5B; Fig. 4.10F). 
The HG state brings with it many deleterious effects, including excess superoxide production (Kaneto 
et al., 2010). Betulinic acid, however, is hypothesized to counterbalance this. Numerous studies have 
proven BA’s ability to reduce ROS levels, however this has not been tested in response to HG-
induced ROS (Szuster-Ciesielska and Kandefer-Szerszeñ, 2005). This current study reveals that BA 
significantly downregulated ROS in response to HG-induced stress, at both concentrations (Fig. 
4.4B). Intriguingly, BA also downregulated ROS in the absence of OS, in the NG state (Fig. 4.4A). 
The ROS damage to macromolecules in the HG state is associated with high levels of lipid 
peroxidation (Asmat et al., 2016). Lipid peroxidation levels were downregulated by BA, in both 
states, at both concentrations (Fig. 4.4C; Fig. 4.4D). Understandably, statistical analysis revealed a 
more significant MDA reduction in the HG state, by BA (Fig. 4.4D). Of further significance, is the 
ability of lipid peroxidation to directly attack cell membranes (Cheeseman, 1993). A significant 
decrease in MDA levels in HG conditions at 5µM and 10µM BA (Fig. 4.4D) coincided with a 
decrease in LDH levels (Fig. 4.2B), implying that BA reduced MDA-induced membrane damage, and 
subsequent LDH release. 
MDA, the by-product of lipid peroxidation, post-translationally carbonylates proteins, resulting in 
irreversible damage (Hauck and Bernlohr, 2016). Betulinic acid’s reduction of MDA levels 
understandably lead to concomitant reduction of protein carbonylation levels. This reduction was, 
likewise to MDA levels, more pronounced in the HG state (Fig. 4.4E; Fig. 4.4F).  
HepG2 cells can be used to detect changes in toxicity at different glucose levels (Kamalian et al., 
2015). The HG state is associated with increased OS biomarkers (MDA and carbonyl levels). 
Consequently, we hypothesize that BA would reduce MDA and protein carbonylation levels more 
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substantially in HG conditions. In line with this, both OS markers were more significantly reduced in 
the HG state, in response to BA treatment (Fig. 4.4D; Fig. 4.4F).  
Although MDA and protein carbonyl levels are regarded as biomarkers of OS, ROS are implicated in 
many other situations. Basal ROS levels are required in the cell as signalling molecules, involved in 
gene transcription and protein synthesis etc. (Kaneto et al., 2010).  
In NG media, BA reduced ROS significantly (Fig. 4.4A), but did not reduce OS biomarkers (MDA 
and protein carbonyls) as significantly (Fig. 4.4C; Fig. 4.4E). This further reduction of ROS beyond 
the baseline, however, may not be particularly deleterious as evidenced by constant TCA, ETC and 
OXPHOS readings present in NG media, implying stable energy levels (Fig. 4.1A; Fig. 4.1C). The 
NG state is not associated with OS, hence BA did not reduce OS markers as significantly in this state. 
Taken together, these results indicate that BA significantly reduced ROS and OS biomarkers, thus 
combatting the highly oxidative state associated with hyperglycaemia.  
The initial part of this study proved BA’s lack of toxicity and anti-ROS activities. We then sought to 
discern the molecular mechanisms behind BA’s anti-ROS action. Lee (2017) proposed a positive 
feedback model in which PPARγ and NRF2 reciprocally transcribe for each other. This model not 
only results in potentiation of the two transcription factors, but of a range of other AOs for which they 
transcribe (Lee, 2017). We hence proceeded to sequentially assess PPARγ and NRF2 levels in 
response to treatment with BA. 
PPARγ upregulation has been widely proven in many HG studies. Additionally, BA binds tightly to 
PPARγ (Brusotti et al., 2017). We thus hypothesized PPARγ as the master regulator of BA’s AO 
response to HG-induced OS. The PPARγ complex binds to specific PPREs on the promoter region of 
the common AO related genes, e.g. SOD2, CAT, UCP2, NRF2, activating their transcription (Lee, 
2017, Kvandova et al., 2016, Pierelli et al., 2017, Polvani et al., 2012, Girnun et al., 2002). This 
current study revealed that BA upregulated PPARγ in both conditions at both concentrations, 
implying interaction (Fig. 4.5A; Fig. 4.5B). Furthermore, BA upregulated PPARγ more significantly 
in HG conditions at 5µM BA (Fig. 4.5B). This optimal upregulation coincided with upregulations in 
the above-mentioned AO-related proteins, implying that BA mounted an AO-response through 
PPARγ to HG stress (Fig. 4.7B; Fig. 4.7D; Fig. 4.8B; Fig. 4.5D). 
Beyond the above proposed positive feedback loop, triterpenes also exert a direct effect on the activity 
of NRF2. Loboda et al. 2012 stated that triterpenoids can activate NRF2 indirectly via signal pathway 
phosphorylation, or via oxidative modification of SH groups (Loboda et al., 2012). Once 
phosphorylated, NRF2 is translocated to the nucleus to exert its AO transcription activity (Loboda et 
al., 2012). Evaluation of our results revealed that both BA treatments of 5µM and 10µM upregulated 
pNRF2 to maximum significance in response to HG stress (Fig. 4.6D). 
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NRF2 exerts its transcription of many AO proteins via direct binding to the ARE on the promoter 
region of their genes. Multiple lines of research revealed presence of ARE complex on many AO-
related genes, e.g. PPARγ, SOD2, CAT, SIRT3, GPx1 (Lee, 2017, Cho et al., 2005, Cho et al., 2010, 
Jeong et al., 2016, Jin et al., 2016, Song et al., 2017). In keeping with this, our study demonstrated 
concomitant upregulations of all of the above proteins and genes, alongside NRF2 gene and protein 
expression (Fig. 4.5B; Fig. 4.5D; Fig. 4.5F;  Fig. 4.7B; Fig. 4.7D; Fig. 4.7F; Fig. 4.10B; Fig. 4.10D). 
We can thus identify NRF2 as one of the factors involved in BA’s heightening of the AO response to 
HG-induced stress. 
An osmotic control of mannitol was included in the western blots of proteins pNRF2, localized to the 
nucleus, and total NRF2, localised in both the cytoplasm and nucleus. NRF2 is considered a master 
regulator and hence its levels determine the corresponding levels of many AO and AO-related 
proteins in this study. Thus, the inert sugar, mannitol, was added as a control to ensure that the effects 
in HG were rightly attributed to BA action, and not due to changed pressure in the cell. No 
significance was found between HG control and osmotic control in both NRF2 states, validating this 
result (Fig. 4.5D; Fig. 4.6D).  
Taken together, our study serves as confirmatory evidence of this positive feedback loop phenomenon 
being enhanced by BA to combat HG induced stress at an optimum concentration of 5µM, evidenced 
by concomitant upregulations of NRF2 and PPARγ as well as the AOs for which they transcribe. 
The link between NRF2 and PPARγ can be further explored via epigenetics. The apt miR124 is 
transcribed for by PPARγ, and exerts AO actions via indirect NRF2 phosphorylation, as well as anti-
inflammatory effects via NFκB repression (Shu and Zhang, 2019, Wang et al., 2017). Upregulations 
of PPARγ, pNRF2 and miR124 coincided with a downregulation of NFκB at 5µM BA in HG 
conditions, suggesting miR124 activity in this study (Fig. 4.5B; Fig. 4.6B; Fig. 4.6D; Fig. 4.9B). This 
further strengthens the link between NRF2 and PPARγ, and is indicative of miR124 reducing ROS-
induced inflammation and enhancing AO transcription. 
The AO nature of BA has previously been explored with Yi et al., (2014) concluding that, in mice, 
BA stimulates the AO system (SOD2, GPx1, GSH), protecting against hepatoxicity and lowering 
MDA levels (Yi et al., 2014). SOD2 protein is responsible for detoxifying superoxide radicals into 
peroxides, to be consequently reduced to water by both CAT and the GSH mechanism (Noori, 2012). 
This current study confirmed that BA exerts an AO response to HG-stress, by demonstrating 
significant upregulations of both SOD2 and CAT at 5µM BA (Fig. 4.7B; Fig. 4.7D). These 
upregulations coincided with a downregulation of ROS and OS biomarkers, implying that these 
proteins successfully exerted their AO-activity (Fig. 4.4B; Fig. 4.4D; Fig. 4.4F).  
The alternate peroxide reduction method involving GPx1 and GSH was also analysed. Upon HG 
stimulation, BA significantly upregulated GPx1 mRNA levels (Fig. 4.7F). Coinciding with this, BA 
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further upregulated GSH levels in HG media, at a prime concentration of 5µM BA (Fig. 4.7H). These 
results suggest that BA upregulated the GpX1/GSH AO mechanism, to reduce HG-induced peroxides 
to H2O. 
 For the most part, BA did not upregulate AO activities in NG media. However, BA upregulated 
GPx1 mRNA levels in NG media at a concentration of 10µM BA (Fig. 4.7E). Lu et al. (2015) 
uncovered that, in unstressed hepatic conditions, NFκB induces GPx1 gene expression, without 
apparent inflammation (Lu et al., 2015). Concomitant upregulations of both GPx1 mRNA and NFκB 
at 10µM BA in NG conditions corroborate this observation (Fig. 4.7E; Fig. 4.9A).  
It should be known that Szuster-Ciesielska and Kandefer-Szerszen (2005) suggested that the AO 
activity of BA is dependent on the level of ROS induction (Szuster-Ciesielska and Kandefer-Szerszeñ, 
2005). A consistent upregulation was evident in the entire AO response (SOD2, CAT, GPx1/GSH) at 
5µM BA treatment in HG conditions, coinciding with lowered ROS, protein carbonyl and MDA 
levels (Fig. 4.4; Fig. 4.7). These results are in line with Szuster-Ciesielska and Kandefer-Szerszen’s 
observation, suggesting the HG state brought high levels of ROS induction, stimulating an intensive 
AO response by BA (Szuster-Ciesielska and Kandefer-Szerszeñ, 2005). 
To further evaluate the AO profile, the transmembrane protein, UCP2, was assessed. UCP2 is 
associated with increased proton leakage, uncoupling ETC from OXPHOS, hence it is proven to 
modulate ATP synthesis and ROS levels (Su et al., 2017). Additionally, UCP2’s effect on ATP and 
NAD+ levels allow it to maintain the mitochondrial steady state (Su et al., 2017). UCP2 fluctuations 
were observed in NG media in Fig. 4.8A. We can thus infer that any alterations in UCP2 levels 
assisted in the maintenance of constant ATP readings observed in Fig. 4.1C and Fig. 4.1D. 
Betulinic acid’s effect on UCP2 is not fully elucidated, with Heiss et al. (2014) concluding that, 
despite BA’s upregulation of UCP2 in the MEF cell line, it is expressed to different degrees in 
different tissues, warranting further research in different cell lines (Heiss et al., 2014). Recent research 
into UCP2’s anti-ROS activities demonstrated that UCP2 is upregulated in HG conditions to combat 
associated ROS (Sosa-Gutiérrez et al., 2018). This current study demonstrated an upregulation at 5µM 
BA, relative to the HG control (Fig. 4.8B). Therefore, we conclude that BA further upregulated UCP2 
expression above this already heightened state, at 5µM concentration, to intensify cytoprotection to 
HG-induced ROS (Fig. 4.8B).  
Although the modulation of UCP2 activity is poorly understood, recent research suggest that PPARγ 
can modulate UCP2 gene and protein levels, utilising it as a key method of ROS reduction (Wang et 
al., 2014). Research into this further elucidated the vital role of UCP2, by demonstrating that 
inhibiting UCP2 lead to a reduction of PPARγ agonist rosiglitazone’s ROS-diminishing capacity. A 
concomitant upregulation at 5µM BA in HG conditions in both PPARγ and UCP2 demonstrated the 
presence of this link in this current study (Fig. 4.5B; Fig. 4.8B). 
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In addition to UCP’s ROS-reducing role, exists its role to promote AO activity. Sosa-Gutierrez et al. 
(2018) suggests that UCP2’s ability to modulate the NAD+/NADH ratio allows it to favour NAD, 
thus promoting SIRT3 deacetylase activity (Sosa-Gutiérrez et al., 2018). 
SIRT3 is aptly titled a metabolic sensor, due to its intrinsic ability to sense NAD+ levels, as well as 
utilise them as a cofactor for its deacetylation function. SIRT3 exerts its AO functions via 
deacetylation of AO proteins, thus activating them (Hirschey et al., 2011a). It has been previously 
proven that OS conditions induce SIRT3. Furthermore, Gounden et al. (2015) demonstrated that HG 
conditions bring about an increase in SIRT3 expression and resultant AO defence in HepG2 cells 
(Gounden et al., 2015). In the current study, it was observed that BA upregulated SIRT3 protein 
expression significantly above the HG control (Fig. 4.10B). These findings imply that BA further 
upregulated an already enhanced SIRT3 at 5µM in HG conditions (Fig. 4.10B).  
Additionally, we explore the SIRT3/PGC1α loop in potentiation of the AO response upon BA 
treatment. The hypothesized involvement of BA in the SIRT3/PGC1α loop in this study originates 
from the relation of NRF2 and SIRT3. PGC1α was found to interact directly with NRF2 at the ARE 
promoter region of SIRT3, enhancing SIRT3 transcription (Song et al., 2017). We propose that BA 
stimulates NRF2 to transcribe for SIRT3, which thus initiates the SIRT3/PGC1α/ERRα/CREB 
positive feedback mechanism. Betulinic acid’s enhancement of both these observations were clearly 
evident at 5µM BA stimulation in HG conditions, where all 3 proteins (NRF2, SIRT3, PGC1α), and 
genes were upregulated (Fig. 4.5D; Fig. 4.10B; Fig. 4.10D; Fig. 4.10F; Fig. 4.10H). These 
observations suggest that BA potentiates the SIRT3/PGC1α positive feedback loop via NRF2 in 
response to HG-stress. This feedback loop enhances AO response, with SIRT3 promoting AO 
activity, and PGC1α promoting AO transcription.  
We report on SIRT3 and PGC1α’s AO involvement. Chen et al. (2011) revealed the concept of 
SIRT3-dependant deacetylation of SOD2, to activate its anti-superoxide capabilities (Chen et al., 
2011). Our results demonstrate an upregulation of both proteins at 5µM BA, demonstrating that BA 
stimulation enhances SIRT3’s deacetylation of SOD2 to further its AO activities (Fig. 4.7B; Fig. 
4.10B). Additionally, many of SIRT3’s AO abilities are indirect, stemming from its activation of 
PGC1α, amongst other proteins (Kong et al., 2010). 
PGC1α is involved in the co-regulation of various AO-related proteins. Valle et al., (2005) 
demonstrated that PGC1α could be found associated with the regulatory promoter sequences of SOD2 
and UCP2 (Valle et al., 2005). Additionally, research has established PGC1α’s control of GPx1 and 
CAT (Iacovelli et al., 2016) . The current study revealed concomitant enhancement of PGC1α and the 
abovementioned AOs at a concentration of 5µM BA in HG conditions. This suggests that BA’s 
upregulation of PGC1α assisted in the amplification of the AO response to combat HG stress (Fig. 
4.7B; Fig. 4.7D; Fig. 4.7F; Fig. 4.8B; Fig. 4.10F).  
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Despite a lack of protein upregulation in NG conditions, mRNA levels of PGC1α and SIRT3 were 
significantly increased (Fig. 4.10A; Fig. 4.10C; Fig. 4.10E; Fig. 4.10G). Research into both proteins 
has demonstrated high levels of post-translational regulation, especially with regards to metabolic 
stress status (Flick and Lüscher, 2012, Luo et al., 2019). This strongly implies that post-translational 
repression occurs , due to lack of metabolic stress in NG conditions, in the current study, preventing 
an increase in protein expression, despite elevated mRNA levels (Fig. 4.10A; Fig. 4.10C; Fig. 4.10E; 
Fig. 4.10G). 
The oxidation of proteins not only result in loss of function, but also result in crosslinking, forming 
aggregates, disrupting metabolism and homeostatic processes, being increasingly linked to T2DM 
(Dalle‐Donne et al., 2006). Mitochondria are protein dense, high traffic organelles, exposed to 
constant levels of ROS, warranting a security mechanism to protein oxidation (Andreyev et al., 2005). 
LONP1 is a proteolytic digestor, implicated in the removal of oxidized proteins from the mitochondria 
(Ngo et al., 2013). Gibellini et al. (2014) concluded that LONP1 is directly deacetylated by SIRT3, 
resulting in its activation for protein degradation (Gibellini et al., 2014). Consistent with this, at 5µM 
BA in HG conditions, upregulations in SIRT3 and LONP1 coincided with significantly low protein 
carbonylation levels (Fig. 4.4F; Fig. 4.10B; Fig. 4.11B). BA’s indirect upregulation of SIRT3 thus 
extends to promote LONP1s proteolysis of protein carbonyls, reducing the toxic environment induced 
by hyperglycaemia. 
LONP1, however, is considered biphasic, and is also implicated in many other functions, including 
mitogenesis, chaperone systems and ETC and ATP maintenance (Ngo et al., 2013). An upregulation 
of LONP1 in NG conditions at 10µM did not correlate with SIRT3 levels, leading us to assume that 
the upregulation was due to other extraneous factors (Fig. 4.11A). 
Another repercussion of HG-induced ROS is that of inflammation. In the HG setting, inflammation 
and ROS are intertwined in a positive feedback loop, with NFκB an important linking protein between 
the two, being stimulated by ROS, and reciprocally stimulating ROS and inflammation (Morgan and 
Liu, 2011, Sharma et al., 2018). NFκB is an easily inducible transcription factor involved in the 
induction of genes for various processes (Zhang et al., 2017). It is also proven to be repressed by all of 
PGC1α, NRF2 and PPARγ (Eisele et al., 2015, Wahli, 2008, Wardyn et al., 2015). Expectedly, low 
levels of NFκB coincided with high levels of PGC1α, NRF2 and PPARγ, its repressors, at 5µM BA in 
response to HG stress (Fig. 4.9B; Fig. 4.5B; Fig. 4.5D; Fig. 4.10F). Additionally, we speculate the 
NFκB downregulation at 5µM BA in HG conditions, may have assisted in reducing the ROS levels 
demonstrated in Figure 4.4B. Furthermore, multiple studies have indicated that LDH can be 
alternatively viewed as a biomarker of inflammation (Wu et al., 2016). NFκB downregulation at 5µM 
BA concentration correlated with previously noted LDH downregulations in this study (Fig. 4.2B; 
Fig. 4.9B). Thus, we deduce that BA’s stimulation of PGC1α, NRF2 and PPARγ repressed NFκB, 
lessening ROS-induced inflammation and resultant membrane damage, noted via downregulation of 
LDH and ROS levels.  
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Previous research involving BA proved its inhibition of NFκB for anti-inflammatory purposes in a 
nontumor cell line and on a diabetic rat-model (Wang et al., 2016). Interestingly, it has also been 
concluded that BA activates NFκB to aid in anti-cancer activity in tumour cell lines (Kasperczyk et 
al., 2005). These confounding studies suggest a possible modulation of NFκB to suit specific 
circumstances (Wang et al., 2016). In the NG model, BA induced an upregulation of NFκB at both 
concentrations (Fig. 4.9A). Constant LDH levels (Fig. 4.2A), however, alluded to a lack of 
inflammation in NG model, hence we can assume that BA exerts differential regulation of NFκB, 
downregulating it to combat HG induced inflammation, and upregulating it otherwise, for extraneous 
purposes. 
 
Taken together, our results highlight 5µM BA as an optimal concentration to enhance the 
cytoprotective machinery to HG induced OS. We further summarize these results and propose a 
model of the mechanism of BA’s cytoprotective action. 
As demonstrated by figure 5.1, BA upregulated PPARγ and phosphorylated NRF2. The PPARγ/NRF2 
feedback loop potentiates transcription of many AO’s including UCP2, SOD2, CAT and GPx1. SOD2 
detoxifies ROS into peroxides, which CAT and GPx1 then reduce to water thus reducing HG-induced 
ROS and resultant OS. UCP2 acts to simultaneously reduce ROS and increase AO response, via 
promoting SIRT3 activity. NRF2 transcribes for SIRT3. SIRT3 deacetylates and activates SOD2 and 
LONP1, promoting AO activity and proteolysis of oxidized proteins. Furthermore, SIRT3 stimulates 
PGC1α, resulting in a positive feedback loop. PGC1α aids in transcription of SOD2, CAT, GPx1 and 
UCP2, further potentiating the AO-profile.  
PPARγ additionally transcribes for miR124, which inhibits NFκB and promotes NRF2 
phosphorylation. Furthermore, PPARγ, NRF2 and PGC1α also directly repress NFκB transcription. 
This combined inhibition of NFκB reduces HG-induced ROS and ROS-induced inflammation.  
This mechanism acts to amplify the AO and anti-ROS response to combat an OS state associated with 




Figure 5.1: Proposed mechanism for BA’s cytoprotective actions to hyperglycaemic induced ROS at 

















CHAPTER 6: CONCLUSION 
6.1) Conclusion 
Taken together, data of this study demonstrates that BA, a lupane-triterpene, has the ability to protect 
human hepatoma cells against HG-induced OS, via modulation of the AO profile at an optimal 
concentration of 5µM. Additionally, we propose a mechanism by which BA exerts its cytoprotective 
effect, originating from the NRF2/PPARγ positive feedback loop. These findings suggest BA as a 
potential adjunctive therapeutic agent for diabetes and diabetes-related complications, which is cost 
effective and readily available. This is of particular significance in developing countries like South 
Africa where the incidence of diabetes is rapidly rising. This study’s limitation of an in vitro model 
opens avenues for further research in a murine model and human testing to consider overall metabolic 
interactions normally prevalent in the in vivo model. 
6.2) Future Studies 
Betulinic acid is an essential component of Peltophorum africanum, a traditional African medicinal 
plant. It would be relevant to examine this plant for additional pharmacologically active compounds. 
Recent research suggests a paradigm shift away from the “adipocentric theory,” in which adipose 
tissue is one of the primary causes of insulin resistance, towards an “endothelial dysfunction theory,” 
in which oxidative stress brings about endothelial inflammation as the primary cause of insulin 
resistance. Thus, this study can be transposed onto a more relevant endothelial cell line to evaluate 
BA’s ability to ameliorate endothelial cell OS in order to combat insulin resistance and CVS 
complications. 
Betulinic acid’s previously researched anti-diabetic effects make BA an interesting candidate to 
evaluate as adjunctive therapy with metformin to combat hyperglycaemia and prevent complications 
in T2DM. Additionally, the HG model could be expanded to include a palmitate-induced insulin 
resistance model to more closely mimic the in vivo diabetic state and thus provide a more accurate and 
appropriate cellular response to OS in response to BA treatment. 
6.3) Limitations  
In this study an in vitro HepG2 model was utilised to assess the AO response to HG induced OS in 
response to BA. Although this model allowed for detailed analysis, a shortcoming is that cells are far 
removed from their natural environment, thus eliminating cellular and metabolic interactions normally 
present in a whole organism. Future studies could entail using a diabetic mouse model in order to 






ADELEKE, G. E. & ADARAMOYE, O. A. 2017. Betulinic acid protects against N-nitrosodimethylamine-
induced redox imbalance in testes of rats. Redox report, 22, 556-562. 
AHN, B.-H., KIM, H.-S., SONG, S., LEE, I. H., LIU, J., VASSILOPOULOS, A., DENG, C.-X. & FINKEL, T. 2008. 
A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proceedings 
of the National Academy of Sciences, 105, 14447-14452. 
ALBANO, E., BELLOMO, G., PAROLA, M., CARINI, R. & DIANZANI, M. U. 1991. Stimulation of lipid 
peroxidation increases the intracellular calcium content of isolated hepatocytes. Biochimica 
et Biophysica Acta (BBA)-Molecular Cell Research, 1091, 310-316. 
ANDREYEV, A. Y., KUSHNAREVA, Y. E. & STARKOV, A. 2005. Mitochondrial metabolism of reactive 
oxygen species. Biochemistry (Moscow), 70, 200-214. 
ANSARI, A., RAHMAN, M. S., SAHA, S. K., SAIKOT, F. K., DEEP, A. & KIM, K. H. 2017. Function of the 
SIRT 3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative 
disease. Aging cell, 16, 4-16. 
APEL, K. & HIRT, H. 2004. Reactive oxygen species: metabolism, oxidative stress, and signal 
transduction. Annu. Rev. Plant Biol., 55, 373-399. 
APPARI, M., CHANNON, K. M. & MCNEILL, E. 2018. Metabolic regulation of adipose tissue 
macrophage function in obesity and diabetes. Antioxidants & redox signaling, 29, 297-312. 
ARONOFF, S. L., BERKOWITZ, K., SHREINER, B. & WANT, L. 2004. Glucose metabolism and regulation: 
beyond insulin and glucagon. Diabetes spectrum, 17, 183-190. 
ARYA, M., SHERGILL, I. S., WILLIAMSON, M., GOMMERSALL, L., ARYA, N. & PATEL, H. R. 2005. Basic 
principles of real-time quantitative PCR. Expert review of molecular diagnostics, 5, 209-219. 
ASMAT, U., ABAD, K. & ISMAIL, K. 2016. Diabetes mellitus and oxidative stress—a concise review. 
Saudi Pharmaceutical Journal, 24, 547-553. 
BERG, A. H., COMBS, T. P. & SCHERER, P. E. 2002. ACRP30/adiponectin: an adipokine regulating 
glucose and lipid metabolism. Trends in Endocrinology & Metabolism, 13, 84-89. 
BERMUDEZ, V., FINOL, F., PARRA, N., PARRA, M., PÉREZ, A., PENARANDA, L., VÍLCHEZ, D., ROJAS, J., 
ARRÁIZ, N. & VELASCO, M. 2010. PPAR-γ agonists and their role in type 2 diabetes mellitus 
management. American journal of therapeutics, 17, 274-283. 
BIRBEN, E., SAHINER, U. M., SACKESEN, C., ERZURUM, S. & KALAYCI, O. 2012. Oxidative stress and 
antioxidant defense. World Allergy Organization Journal, 5, 9-19. 
BONEN, A., HOLLOWAY, G. P., TANDON, N. N., HAN, X.-X., MCFARLAN, J., GLATZ, J. F. & LUIKEN, J. J. 
2009. Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol 
and fatty acid oxidation in lean and Zucker diabetic fatty rats. American Journal of 
Physiology-Regulatory, Integrative and Comparative Physiology, 297, R1202-R1212. 
BOTA, D. A. & DAVIES, K. J. 2016. Mitochondrial Lon protease in human disease and aging: Including 
an etiologic classification of Lon-related diseases and disorders. Free Radical Biology and 
Medicine, 100, 188-198. 
BROWNLEE, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 
414, 813. 
BRUSOTTI, G., MONTANARI, R., CAPELLI, D., CATTANEO, G., LAGHEZZA, A., TORTORELLA, P., 
LOIODICE, F., PEIRETTI, F., BONARDO, B. & PAIARDINI, A. 2017. Betulinic acid is a PPARγ 
antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis. 
Scientific reports, 7, 5777. 
BRYAN, H. K., OLAYANJU, A., GOLDRING, C. E. & PARK, B. K. 2013. The Nrf2 cell defence pathway: 
Keap1-dependent and-independent mechanisms of regulation. Biochemical pharmacology, 
85, 705-717. 
CARVALHO, F. 2017. Role of Nrf2 in the Regulation of Ppar Expression in Mice. 
72 
 
CASTELLANO, J. M., GUINDA, A., DELGADO, T., RADA, M. & CAYUELA, J. A. 2013. Biochemical basis of 
the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes. Diabetes, 62, 
1791-1799. 
CASTRO, A. J. G., FREDERICO, M. J. S., CAZAROLLI, L. H., BRETANHA, L. C., DE CARVALHO TAVARES, L., 
DA SILVA BUSS, Z., DUTRA, M. F., DE SOUZA, A. Z. P., PIZZOLATTI, M. G. & SILVA, F. R. M. B. 
2014. Betulinic acid and 1, 25 (OH) 2 vitamin D3 share intracellular signal transduction in 
glucose homeostasis in soleus muscle. The international journal of biochemistry & cell 
biology, 48, 18-27. 
CHEESEMAN, K. 1993. Mechanisms and effects of lipid peroxidation. Molecular Aspects of Medicine, 
14, 191-197. 
CHEN, Y.-L., FU, L., WEN, X., WANG, X. Y., LIU, J., CHENG, Y. & HUANG, J. 2014. Sirtuin-3 (SIRT3), a 
therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell death & 
disease, 5, e1047. 
CHEN, Y., ZHANG, J., LIN, Y., LEI, Q., GUAN, K. L., ZHAO, S. & XIONG, Y. 2011. Tumour suppressor 
SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO 
reports, 12, 534-541. 
CHO, H.-Y., GLADWELL, W., WANG, X., CHORLEY, B., BELL, D., REDDY, S. P. & KLEEBERGER, S. R. 2010. 
Nrf2-regulated PPARγ expression is critical to protection against acute lung injury in mice. 
American journal of respiratory and critical care medicine, 182, 170-182. 
CHO, H.-Y., REDDY, S. P., DEBIASE, A., YAMAMOTO, M. & KLEEBERGER, S. R. 2005. Gene expression 
profiling of NRF2-mediated protection against oxidative injury. Free Radical Biology and 
Medicine, 38, 325-343. 
CHO, N., SHAW, J., KARURANGA, S., HUANG, Y., DA ROCHA FERNANDES, J., OHLROGGE, A. & 
MALANDA, B. 2018. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 
and projections for 2045. Diabetes research and clinical practice, 138, 271-281. 
CHORLEY, B. N., CAMPBELL, M. R., WANG, X., KARACA, M., SAMBANDAN, D., BANGURA, F., XUE, P., 
PI, J., KLEEBERGER, S. R. & BELL, D. A. 2012. Identification of novel NRF2-regulated genes by 
ChIP-Seq: influence on retinoid X receptor alpha. Nucleic acids research, 40, 7416-7429. 
COLLINS, K. H., HERZOG, W., MACDONALD, G. Z., REIMER, R. A., RIOS, J. L., SMITH, I. C., ZERNICKE, R. 
F. & HART, D. A. 2018. Obesity, metabolic syndrome, and musculoskeletal disease: common 
inflammatory pathways suggest a central role for loss of muscle integrity. Frontiers in 
physiology, 9, 112. 
CONSOLI, A. 1992. Role of liver in pathophysiology of NIDDM. Diabetes care, 15, 430-441. 
CZECH, M. P. 1985. The nature and regulation of the insulin receptor: structure and function. Annual 
Review of Physiology, 47, 357-381. 
DALLE‐DONNE, I., ALDINI, G., CARINI, M., COLOMBO, R., ROSSI, R. & MILZANI, A. 2006. Protein 
carbonylation, cellular dysfunction, and disease progression. Journal of cellular and 
molecular medicine, 10, 389-406. 
DAVID, J. A., RIFKIN, W. J., RABBANI, P. S. & CERADINI, D. J. 2017. The Nrf2/Keap1/ARE pathway and 
oxidative stress as a therapeutic target in type II diabetes mellitus. Journal of diabetes 
research, 2017. 
DE MELO, C. L. L., QUEIROZ, M. G. R., ARRUDA FILHO, A. C. V., RODRIGUES, A. M., DE SOUSA, D. F., 
ALMEIDA, J. G. L., PESSOA, O. D. L., SILVEIRA, E. R., MENEZES, D. B. & MELO, T. S. 2009. 
Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in 
mice fed a high-fat diet. Journal of agricultural and food chemistry, 57, 8776-8781. 
DEVASAGAYAM, T., BOLOOR, K. & RAMASARMA, T. 2003. Methods for estimating lipid peroxidation: 
an analysis of merits and demerits. Indian journal of biochemistry & biophysics, 40, 300-308. 
DONATO, M. T., TOLOSA, L. & GÓMEZ-LECHÓN, M. J. 2015. Culture and functional characterization 
of human hepatoma HepG2 cells. Protocols in In Vitro Hepatocyte Research. Springer. 
73 
 
EISELE, P. S., FURRER, R., BEER, M. & HANDSCHIN, C. 2015. The PGC-1 coactivators promote an anti-
inflammatory environment in skeletal muscle in vivo. Biochemical and biophysical research 
communications, 464, 692-697. 
FERNANDES, J., WEDDLE, A., KINTER, C. S., HUMPHRIES, K. M., MATHER, T., SZWEDA, L. I. & KINTER, 
M. 2015. Lysine acetylation activates mitochondrial aconitase in the heart. Biochemistry, 54, 
4008-4018. 
FINLEY, L. W., HAAS, W., DESQUIRET-DUMAS, V., WALLACE, D. C., PROCACCIO, V., GYGI, S. P. & 
HAIGIS, M. C. 2011. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase 
activity. PloS one, 6, e23295. 
FLICK, F. & LÜSCHER, B. 2012. Regulation of sirtuin function by posttranslational modifications. 
Frontiers in pharmacology, 3, 29. 
FROHNERT, B. I. & BERNLOHR, D. A. 2013. Protein carbonylation, mitochondrial dysfunction, and 
insulin resistance. Advances in nutrition, 4, 157-163. 
FU, L., ZHANG, S., LI, N., WANG, J., ZHAO, M., SAKAI, J., HASEGAWA, T., MITSUI, T., KATAOKA, T. & 
OKA, S. 2005. Three New Triterpenes from Nerium o leander and Biological Activity of the 
Isolated Compounds. Journal of natural products, 68, 198-206. 
GIBELLINI, L., PINTI, M., BERETTI, F., PIERRI, C. L., ONOFRIO, A., RICCIO, M., CARNEVALE, G., DE BIASI, 
S., NASI, M. & TORELLI, F. 2014. Sirtuin 3 interacts with Lon protease and regulates its 
acetylation status. Mitochondrion, 18, 76-81. 
GIRNUN, G. D., DOMANN, F. E., MOORE, S. A. & ROBBINS, M. E. 2002. Identification of a functional 
peroxisome proliferator-activated receptor response element in the rat catalase promoter. 
Molecular Endocrinology, 16, 2793-2801. 
GORRINI, C., HARRIS, I. S. & MAK, T. W. 2013. Modulation of oxidative stress as an anticancer 
strategy. Nature reviews Drug discovery, 12, 931-947. 
GOUNDEN, S. & CHUTURGOON, A. 2017. Curcumin upregulates antioxidant defense, lon protease, 
and heat-shock protein 70 under hyperglycemic conditions in human hepatoma cells. 
Journal of medicinal food, 20, 465-473. 
GOUNDEN, S., PHULUKDAREE, A., MOODLEY, D. & CHUTURGOON, A. 2015. Increased SIRT3 
expression and antioxidant defense under hyperglycemic conditions in HepG2 cells. 
Metabolic syndrome and related disorders, 13, 255-263. 
GROTTO, D., MARIA, L. S., VALENTINI, J., PANIZ, C., SCHMITT, G., GARCIA, S. C., POMBLUM, V. J., 
ROCHA, J. B. T. & FARINA, M. 2009. Importance of the lipid peroxidation biomarkers and 
methodological aspects for malondialdehyde quantification. Quimica Nova, 32, 169-174. 
GUZIK, T. J. & COSENTINO, F. 2018. Epigenetics and immunometabolism in diabetes and aging. 
Antioxidants & redox signaling, 29, 257-274. 
HAUCK, A. K. & BERNLOHR, D. A. 2016. Oxidative stress and lipotoxicity. Journal of lipid research, 57, 
1976-1986. 
HEISS, E. H., KRAMER, M. P., ATANASOV, A. G., BERES, H., SCHACHNER, D. & DIRSCH, V. M. 2014. 
Glycolytic switch in response to betulinic acid in non-cancer cells. PloS one, 9, e115683. 
HIRSCHEY, M., SHIMAZU, T., HUANG, J.-Y., SCHWER, B. & VERDIN, E. SIRT3 regulates mitochondrial 
protein acetylation and intermediary metabolism.  Cold Spring Harbor symposia on 
quantitative biology, 2011a. Cold Spring Harbor Laboratory Press, 267-277. 
HIRSCHEY, M. D., SHIMAZU, T., JING, E., GRUETER, C. A., COLLINS, A. M., AOUIZERAT, B., 
STANČÁKOVÁ, A., GOETZMAN, E., LAM, M. M. & SCHWER, B. 2011b. SIRT3 deficiency and 
mitochondrial protein hyperacetylation accelerate the development of the metabolic 
syndrome. Molecular cell, 44, 177-190. 
HUANG, J., TABBI-ANNENI, I., GUNDA, V. & WANG, L. 2010a. Transcription factor Nrf2 regulates SHP 
and lipogenic gene expression in hepatic lipid metabolism. American Journal of Physiology-
Gastrointestinal and Liver Physiology, 299, G1211-G1221. 
HUANG, T., LONG, M. & HUO, B. 2010b. Competitive binding to cuprous ions of protein and BCA in 
the bicinchoninic acid protein assay. The open biomedical engineering journal, 4, 271. 
74 
 
IACOVELLI, J., ROWE, G. C., KHADKA, A., DIAZ-AGUILAR, D., SPENCER, C., ARANY, Z. & SAINT-GENIEZ, 
M. 2016. PGC-1α induces human RPE oxidative metabolism and antioxidant capacity. 
Investigative ophthalmology & visual science, 57, 1038-1051. 
IGHODARO, O. & AKINLOYE, O. 2018. First line defence antioxidants-superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire 
antioxidant defence grid. Alexandria Journal of Medicine, 54, 287-293. 
JÄGER, S., TROJAN, H., KOPP, T., LASZCZYK, M. & SCHEFFLER, A. 2009. Pentacyclic triterpene 
distribution in various plants–rich sources for a new group of multi-potent plant extracts. 
Molecules, 14, 2016-2031. 
JEONG, Y.-H., PARK, J.-S., KIM, D.-H. & KIM, H.-S. 2016. Lonchocarpine increases Nrf2/ARE-mediated 
antioxidant enzyme expression by modulating AMPK and MAPK signaling in brain astrocytes. 
Biomolecules & therapeutics, 24, 581. 
JIN, C. H., SO, Y. K., HAN, S. N. & KIM, J.-B. 2016. Isoegomaketone upregulates heme oxygenase-1 in 
RAW264. 7 cells via ROS/p38 MAPK/Nrf2 pathway. Biomolecules & therapeutics, 24, 510. 
KABEL, A. M. 2014. Free radicals and antioxidants: role of enzymes and nutrition. World Journal of 
Nutrition and Health, 2, 35-38. 
KALYANARAMAN, B., DARLEY-USMAR, V., DAVIES, K. J., DENNERY, P. A., FORMAN, H. J., GRISHAM, 
M. B., MANN, G. E., MOORE, K., ROBERTS II, L. J. & ISCHIROPOULOS, H. 2012. Measuring 
reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. 
Free Radical Biology and Medicine, 52, 1-6. 
KAMALIAN, L., CHADWICK, A. E., BAYLISS, M., FRENCH, N. S., MONSHOUWER, M., SNOEYS, J. & PARK, 
B. K. 2015. The utility of HepG2 cells to identify direct mitochondrial dysfunction in the 
absence of cell death. Toxicology in vitro, 29, 732-740. 
KANETO, H., KATAKAMI, N., MATSUHISA, M. & MATSUOKA, T.-A. 2010. Role of reactive oxygen 
species in the progression of type 2 diabetes and atherosclerosis. Mediators of 
inflammation, 2010. 
KASPERCZYK, H., LA FERLA-BRÜHL, K., WESTHOFF, M. A., BEHREND, L., ZWACKA, R. M., DEBATIN, K.-
M. & FULDA, S. 2005. Betulinic acid as new activator of NF-κB: molecular mechanisms and 
implications for cancer therapy. Oncogene, 24, 6945. 
KEY, J., KOHLI, A., BÁRCENA, C., LÓPEZ-OTÍN, C., HEIDLER, J., WITTIG, I. & AUBURGER, G. 2019. Global 
Proteome of LonP1+/− Mouse Embryonal Fibroblasts Reveals Impact on Respiratory Chain, 
but No Interdependence between Eral1 and Mitoribosomes. International journal of 
molecular sciences, 20, 4523. 
KIM, J.-H., NA, H.-J., KIM, C.-K., KIM, J.-Y., HA, K.-S., LEE, H., CHUNG, H.-T., KWON, H. J., KWON, Y.-G. 
& KIM, Y.-M. 2008. The non-provitamin A carotenoid, lutein, inhibits NF-κB-dependent gene 
expression through redox-based regulation of the phosphatidylinositol 3-kinase/PTEN/Akt 
and NF-κB-inducing kinase pathways: role of H2O2 in NF-κB activation. Free Radical Biology 
and Medicine, 45, 885-896. 
KIM, K.-D., JUNG, H.-Y., RYU, H., KIM, B., JEON, J., YOO, H., PARK, C., CHOI, B.-H., HYUN, C.-K. & KIM, 
K.-T. 2019. Betulinic acid inhibits high-fat diet-induced obesity and improves energy balance 
by activating AMPK. Nutrition, Metabolism and Cardiovascular Diseases, 29, 409-420. 
KONG, X., WANG, R., XUE, Y., LIU, X., ZHANG, H., CHEN, Y., FANG, F. & CHANG, Y. 2010. Sirtuin 3, a 
new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial 
biogenesis. PloS one, 5, e11707. 
KUMAR, P., NAGARAJAN, A. & UCHIL, P. D. 2018. Analysis of cell viability by the lactate 
dehydrogenase assay. Cold Spring Harbor Protocols, 2018, pdb. prot095497. 
KURIEN, B. T. & SCOFIELD, R. H. 2006. Western blotting. Methods, 38, 283-293. 
KVANDOVA, M., MAJZÚNOVÁ, M. & DOVINOVÁ, I. 2016. The Role of PPAR [gamma] in 
Cardiovascular Diseases. Physiological research, 65, S343. 
LEE, C. 2017. Collaborative power of Nrf2 and PPARγ activators against metabolic and drug-induced 
oxidative injury. Oxidative medicine and cellular longevity, 2017. 
75 
 
LEICK, L., FENTZ, J., BIENSØ, R. S., KNUDSEN, J. G., JEPPESEN, J., KIENS, B., WOJTASZEWSKI, J. F. & 
PILEGAARD, H. 2010. PGC-1α is required for AICAR-induced expression of GLUT4 and 
mitochondrial proteins in mouse skeletal muscle. American Journal of Physiology-
Endocrinology and Metabolism, 299, E456-E465. 
LEYVRAZ, C., SUTER, M., VERDUMO, C., CALMES, J. M., PAROZ, A., DARIMONT, C., GAILLARD, R., 
PRALONG, F. & GIUSTI, V. 2010. Selective effects of PPARγ agonists and antagonists on 
human pre‐adipocyte differentiation. Diabetes, Obesity and Metabolism, 12, 195-203. 
LI, Z., GENG, Y.-N., JIANG, J.-D. & KONG, W.-J. 2014. Antioxidant and anti-inflammatory activities of 
berberine in the treatment of diabetes mellitus. Evidence-Based Complementary and 
Alternative Medicine, 2014. 
LIU, J., LI, J., LI, W.-J. & WANG, C.-M. 2013. The role of uncoupling proteins in diabetes mellitus. 
Journal of diabetes research, 2013. 
LIU, Y., FISKUM, G. & SCHUBERT, D. 2002. Generation of reactive oxygen species by the 
mitochondrial electron transport chain. Journal of neurochemistry, 80, 780-787. 
LIU, Z., DOU, W., ZHENG, Y., WEN, Q., QIN, M., WANG, X., TANG, H., ZHANG, R., LV, D. & WANG, J. 
2016. Curcumin upregulates Nrf2 nuclear translocation and protects rat hepatic stellate cells 
against oxidative stress. Molecular medicine reports, 13, 1717-1724. 
LIVAK, K. J. & SCHMITTGEN, T. D. 2001. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2− ΔΔCT method. methods, 25, 402-408. 
LOBODA, A., ROJCZYK-GOLEBIEWSKA, E., BEDNARCZYK-CWYNAR, B., LUCJUSZ, Z., JOZKOWICZ, A. & 
DULAK, J. 2012. Targeting Nrf2-mediated gene transcription by triterpenoids and their 
derivatives. Biomolecules & therapeutics, 20, 499. 
LOVEN, D., SCHEDL, H., WILSON, H., DAABEES, T. T., STEGINK, L. D., DIEKUS, M. & OBERLEY, L. 1986. 
Effect of insulin and oral glutathione on glutathione levels and superoxide dismutase 
activities in organs of rats with streptozocin-induced diabetes. Diabetes, 35, 503-507. 
LU, H., LEI, X. & ZHANG, Q. 2015. Moderate activation of IKK2-NF-kB in unstressed adult mouse liver 
induces cytoprotective genes and lipogenesis without apparent signs of inflammation or 
fibrosis. BMC gastroenterology, 15, 94. 
LÜ, J. M., LIN, P. H., YAO, Q. & CHEN, C. 2010. Chemical and molecular mechanisms of antioxidants: 
experimental approaches and model systems. Journal of cellular and molecular medicine, 14, 
840-860. 
LUO, X., LIAO, C., QUAN, J., CHENG, C., ZHAO, X., BODE, A. M. & CAO, Y. 2019. Posttranslational 
regulation of PGC‐1α and its implication in cancer metabolism. International journal of 
cancer. 
LUSHCHAK, V. I. 2012. Glutathione homeostasis and functions: potential targets for medical 
interventions. Journal of amino acids, 2012. 
MAHMOOD, T. & YANG, P.-C. 2012. Western blot: technique, theory, and trouble shooting. North 
American journal of medical sciences, 4, 429. 
MERCIER, Y., GATELLIER, P. & RENERRE, M. 2004. Lipid and protein oxidation in vitro, and 
antioxidant potential in meat from Charolais cows finished on pasture or mixed diet. Meat 
Science, 66, 467-473. 
MERSCH-SUNDERMANN, V., KNASMÜLLER, S., WU, X.-J., DARROUDI, F. & KASSIE, F. 2004. Use of a 
human-derived liver cell line for the detection of cytoprotective, antigenotoxic and 
cogenotoxic agents. Toxicology, 198, 329-340. 
MOGHADDAM, M. G., AHMAD, F. B. H. & SAMZADEH-KERMANI, A. 2012. Biological activity of 
betulinic acid: a review. Pharmacology & Pharmacy, 3, 119. 
MOKABBER, H., NAJAFZADEH, N. & MOHAMMADZADEH VARDIN, M. 2019. miR‐124 promotes neural 
differentiation in mouse bulge stem cells by repressing Ptbp1 and Sox9. Journal of cellular 
physiology, 234, 8941-8950. 




MORGAN, M. J. & LIU, Z.-G. 2011. Crosstalk of reactive oxygen species and NF-κB signaling. Cell 
research, 21, 103. 
MUKHERJEE, A., MORALES-SCHEIHING, D., BUTLER, P. C. & SOTO, C. 2015. Type 2 diabetes as a 
protein misfolding disease. Trends in molecular medicine, 21, 439-449. 
NGO, J. K., POMATTO, L. C. & DAVIES, K. J. 2013. Upregulation of the mitochondrial Lon Protease 
allows adaptation to acute oxidative stress but dysregulation is associated with chronic 
stress, disease, and aging. Redox biology, 1, 258-264. 
NISHIKAWA, T., EDELSTEIN, D., DU, X. L., YAMAGISHI, S.-I., MATSUMURA, T., KANEDA, Y., YOREK, M. 
A., BEEBE, D., OATES, P. J. & HAMMES, H.-P. 2000. Normalizing mitochondrial superoxide 
production blocks three pathways of hyperglycaemic damage. Nature, 404, 787. 
NISHIKORI, M. 2005. Classical and alternative NF-κB activation pathways and their roles in lymphoid 
malignancies. Journal of clinical and experimental hematopathology, 45, 15-24. 
NOORI, S. 2012. An overview of oxidative stress and antioxidant defensive system. Open access 
scientific reports, 1, 1-9. 
ORGANIZATION, W. H. 2018. Global health estimates 2016: disease burden by cause, age, sex, by 
country and by region, 2000–2016. Geneva: World Health Organization. 
PATEL, S. & SANTANI, D. 2009. Role of NF-κB in the pathogenesis of diabetes and its associated 
complications. Pharmacological Reports, 61, 595-603. 
PESTANA, E., BELAK, S., DIALLO, A., CROWTHER, J. R. & VILJOEN, G. J. 2010. Early, rapid and sensitive 
veterinary molecular diagnostics-real time PCR applications, Springer Science & Business 
Media. 
PHANIENDRA, A., JESTADI, D. B. & PERIYASAMY, L. 2015. Free radicals: properties, sources, targets, 
and their implication in various diseases. Indian journal of clinical biochemistry, 30, 11-26. 
PHEIFFER, C., PILLAY-VAN WYK, V., JOUBERT, J. D., LEVITT, N., NGLAZI, M. D. & BRADSHAW, D. 2018. 
The prevalence of type 2 diabetes in South Africa: a systematic review protocol. BMJ open, 
8, e021029. 
PIERELLI, G., STANZIONE, R., FORTE, M., MIGLIARINO, S., PERELLI, M., VOLPE, M. & RUBATTU, S. 
2017. Uncoupling protein 2: A key player and a potential therapeutic target in vascular 
diseases. Oxidative medicine and cellular longevity, 2017. 
PINTI, M., GIBELLINI, L., NASI, M., DE BIASI, S., BORTOLOTTI, C. A., IANNONE, A. & COSSARIZZA, A. 
2016. Emerging role of Lon protease as a master regulator of mitochondrial functions. 
Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1857, 1300-1306. 
POLVANI, S., TAROCCHI, M. & GALLI, A. 2012. PPARγ and oxidative stress: Con (β) catenating NRF2 
and FOXO. PPAR research, 2012. 
POWELL, S. R., WANG, P., DIVALD, A., TEICHBERG, S., HARIDAS, V., MCCLOSKEY, T. W., DAVIES, K. J. & 
KATZEFF, H. 2005. Aggregates of oxidized proteins (lipofuscin) induce apoptosis through 
proteasome inhibition and dysregulation of proapoptotic proteins. Free Radical Biology and 
Medicine, 38, 1093-1101. 
PURDEL, N. C., MARGINA, D. & ILIE, M. 2014. Current methods used in the protein carbonyl assay. 
Annual Research & Review in Biology, 4, 2015-2026. 
QIU, S., FENG, Y., LESAGE, G., ZHANG, Y., STUART, C., HE, L., LI, Y., CAUDLE, Y., PENG, Y. & YIN, D. 
2015. Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by 
modulating P65 and TRAF6. The Journal of Immunology, 194, 1021-1030. 
RAHMAN, I., KODE, A. & BISWAS, S. K. 2006. Assay for quantitative determination of glutathione and 
glutathione disulfide levels using enzymatic recycling method. Nature protocols, 1, 3159. 
REDDY, R. C. & STANDIFORD, T. J. 2010. Nrf2 and PPARγ: PPARtnering against oxidant-induced lung 
injury. American Thoracic Society. 
REISMAN, S. A., ALEKSUNES, L. M. & KLAASSEN, C. D. 2009. Oleanolic acid activates Nrf2 and protects 
from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. 
Biochemical pharmacology, 77, 1273-1282. 
77 
 
RHINESMITH, T., TURKETTE, T. & ROOT-BERNSTEIN, R. 2017. Rapid Non-Enzymatic Glycation of the 
Insulin Receptor under Hyperglycemic Conditions Inhibits Insulin Binding In Vitro: 
Implications for Insulin Resistance. International journal of molecular sciences, 18, 2602. 
RISS, T. L., MORAVEC, R. A., NILES, A. L., DUELLMAN, S., BENINK, H. A., WORZELLA, T. J. & MINOR, L. 
2016. Cell viability assays. Assay Guidance Manual [Internet]. Eli Lilly & Company and the 
National Center for Advancing Translational Sciences. 
ROLO, A. P. & PALMEIRA, C. M. 2006. Diabetes and mitochondrial function: role of hyperglycemia 
and oxidative stress. Toxicology and applied pharmacology, 212, 167-178. 
ROSEN, E. D. & SPIEGELMAN, B. M. 2001. PPARγ: a nuclear regulator of metabolism, differentiation, 
and cell growth. Journal of Biological Chemistry, 276, 37731-37734. 
RUI, L. 2011. Energy metabolism in the liver. Comprehensive physiology, 4, 177-197. 
SAHA, S. S. & GHOSH, M. 2012. Antioxidant and anti-inflammatory effect of conjugated linolenic acid 
isomers against streptozotocin-induced diabetes. British Journal of Nutrition, 108, 974-983. 
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Bicinchoninic Acid (BCA) Assay 
 
Figure 6: Standard curve displaying known concentrations of bovine serum albumin (BSA) used to 
extrapolate the concentration of protein present in sample. 













2,4255 2,849736 126,3275 73,67253 
2,3005 2,692819 133,6889 66,31113 
2,2105 2,579839 139,5436 60,45643 
2,321 2,718554 132,4233 67,57665 
2,5765 3,039292 118,4486 81,55136 
2,4365 2,863545 125,7183 74,28171 
2,458 2,890535 124,5444 75,45557 
2,443 2,871705 125,3611 74,63892 
2,2385 2,614989 137,6679 62,3321 
2,217 2,587999 139,1036 60,89639 
2,4539 2,885388 124,7666 75,23341 
 
  













25µM Betulinic Acid treatment 
Literature proved presence of toxicity above 21µM, however, our MTT assay did not reproduce that 
observation, proving to be viable at all concentrations between 5 and 150µM. Hence, we additionally 
tested a 25µM BA concentration for the majority of our assays, as supplementary information to 
assess its cytoprotective capacity. It did not demonstrate toxicity, however it did not upregulate 
cytoprotective machinery to the same degree as 5µM and 10µM. 
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Figure 7: The H2DCF-DA assay quantifying intracellular ROS levels in response to BA 
administration in a A) normoglycaemic and B) hyperglycaemic model. Lipid peroxidation by-product, 
MDA, quantified via a TBARS assay in both C) normoglycaemic and D) hyperglycaemic media. PCA 
assay quantifying protein carbonyl concentrations as an effect of ROS and lipid peroxidation, in E) 
82 
 
normoglycaemic (p<0.0001) and F) hyperglycaemic media. #p<0.05; ##p<0.001; ###p<0.0001 relative 
to negative controls. 
mRNA expression 
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Figure 8: mRNA expression of GPx1 in A) normoglycaemic and B) hyperglycaemic conditions, 
PGC1α in C) normoglycaemic and D) hyperglycaemic conditions,  NRF2 in E) normoglycaemic and 
F) hyperglycaemic conditions, SIRT3 in G) normoglycaemic and H) hyperglycaemic conditions, 
miR124 in I) normoglycaemic and J) hyperglycaemic conditions #p<0.05; ##p<0.001; ###p<0.0001 
relative to negative controls. 
Western Blots 
























































































































2.5 ### ### ###

















































































1.5 ### ### ###

























































































































































































































Figure 9: Protein expression of IRβ in A) normoglycaemic and B) hyperglycaemic conditions, PGC1α 
in C) normoglycaemic and D) hyperglycaemic conditions, NFκB in E) normoglycaemic and F) 
hyperglycaemic conditions, PPARγ in G) normoglycaemic and H) hyperglycaemic conditions, pNRF2 
in I) normoglycaemic and J) hyperglycaemic conditions, NRF2 in K) normoglycaemic and L) 
hyperglycaemic conditions, CAT in M) normoglycaemic and N) hyperglycaemic conditions, SOD2 in 
O) normoglycaemic and P) hyperglycaemic conditions, LONP1 in Q) normoglycaemic and R) 
hyperglycaemic conditions, SIRT3 in S) normoglycaemic and T) hyperglycaemic conditions, UCP2 in 
U) normoglycaemic and V) hyperglycaemic conditions. #p<0.05; ##p<0.001; ###p<0.0001 relative to 
negative controls 
